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Abstract 
The medical and bioindustrial applications of pluripotent stem cells rely on our 
understanding of their biology. Pluripotent stem cell lines derived from embryos in 
different stages depend on distinct signalling pathways. Embryonic stem cells (ESCs), 
derived from the inner cell mass (ICM) of preimplantation embryos, are dependent on 
LIF/STAT3 signalling, while epiblast stem cells (EpiSCs), established from the 
postimplantation embryos, require Activin A/Smad2/3 signalling. Recent studies 
revealed the presence of intermediate pluripotent stem cell populations. Their growth 
factor responsiveness, gene expression pattern and associated chromatic signatures, are 
compatible with the state intermediate between ESCs and EpiSCs. However, it remains 
unknown whether such cell populations represent a stable clonally intermediate cell 
state. In this thesis, I describe the discovery and characterization of novel stem cell lines 
displaying gene expression pattern intermediate between ESCs and EpiSCs. These cells 
respond to LIF/STAT3 as well as Activin/Smad2/3 signalling at single cell level. They 
can integrate into the ICM and generate chimeric embryos. In keeping with a more 
advanced differentiation stage than that of ESCs, the LIF/Activin dual responsive stem 
cells showed accelerated temporal gene expression kinetics during in vitro 
differentiation in embryo bodies. I found that these properties are shared by some 
induced pluripotent stem cell (iPSC) lines. The notion of an intermediate state was 
13
consolidated by a genome-wide microarray profiling. The hierarchical clustering 
analysis grouped LIF/Activin dual responsive stem cells together into a cluster 
intermediate between ESCs and EpiSCs. These findings advanced our understanding of 
the regulation of pluripotency. A better understanding of distinct differentiation state of 
pluripotent stem cells and their signalling responsiveness is crucial for developing 
tailored strategies for lineage/cell type differentiation.  
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Chapter 1 General Introduction 
 
1. 1 Generation of pluripotent cell population in early staged embryos 
The ability of a cell to generate all of the cell types of an embryo and adult, without 
self-organizing potential to give rise to the whole organism, is defined as pluripotency 
(Niwa, 2007). Pluripotency is a property of the cells in early-staged embryo.  
 
1.1.1 Totipotency in early blastomeres.  
After fertilization, the continuous mitotic divisions of a zygote result in a group of 
cells called blastomeres. The early blastomeres are totipotent, allowing single cell to 
develop into an entire progeny. In mice, it has been shown that a single blastomere of a 
2-cell embryo is totipotent (Tarkowski, 1959). A single blastomere of a 4-cell embryo 
can develop into a blastocyst (Tarkowski and Wroblewska, 1967), but will die soon 
because of its small size and insufficient number of embryonic cells (Rossant, 1976).  
 
1.1.2 Pluripotency of morula- and blastocyst-staged embryos 
At the 8-cell stage in mice, the embryo undergoes a process known as compaction 
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to form a compact smooth spherical structure called morula. The outer cells of the 
compact morula form tight junctions (Ducibella et al., 1975). These tight junctions 
result in a seal that resisits ion and antibody, creating a physical barrier between the 
inner apolar cells and the maternal environment (Magnuson et al., 1978).  
After compaction, the intercellular contacts strengthen between the outer layer of 
the embryo and a true epithelium is formed. Na+/K+-ATPases in the basal membrane 
actively transports sodium ions and accumulates fluid into a cavity of embryo (Watson 
and Kidder, 1988). The morula then begins expanding and a fluid-filled cavity, the 
blastocoelic cavity, is formed on one side of the embryo in a process known as 
cavitation. The descendants of the outer and inner cell population of the morula 
compose the outer trophoectoderm (TE) layer and inner cell mass (ICM), respectively 
(Fleming, 1987). 
The TE descendants form extraembryonic structures such as placenta. The ICM 
forms a bilaminar structure composed of hypoblast, the cells closer to the blastocoelic 
cavity, and epiblast, the cells closer to the TE. The descendants of hypoblast give rise to 
extraembryonic tissue yolk sac (Gardner, 1982; Johnson and Ziomek, 1981). Neither 
TE nor hypoblast cells are capable to contribute to the embryo proper. The early 
epiblast is a cluster of 10–20 unspecialized cells sandwiched between the TE and the 
hypoblast and then generates the entire fetus (Gardner, 1982; Johnson and Ziomek, 
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1981). The isolated epiblast cells at preimplantation stage are capable to contribute to 
all cell lineage and form chimera if introduced into a recipient blastocyst (Gardner, 
1998).  
At the time of implantation (4.5 days post coitus, d.p.c. in mouse), the ICM cells 
initiate a rapid proliferation resulting in expansion of the pluripotent cell population 
(Snow, 1977). Through the process of gastrulation, epiblast gives rise to the mesoderm, 
ectoderm and endoderm of the embryo, germ cells and remaining extraembryonic 
tissue (Gardner and Rossant, 1979). It has been shown that alteration of developmental 
potential and gene expression exist between preimplantation ICM and postimplantation 
epiblast. Compared to ICM, postimplantation epiblast exhibits an upregulation of the 
Fgf5 and down regulation of the Rex1 (Haub and Goldfarb, 1991; Hebert et al., 1991; 
Rogers et al., 1991). Postimplantation epiblast cells are unable to contribute to embryo 
when introduced into host blastocysts (Gardner et al., 1985).  
 
1.2 Pluripotent stem cell lines 
Stable pluripotent cell lines can be derived from embryo or teratocarcinoma by 
culture condition, or generated from somatic cells by introduction of transcription 
factors.  
18
 
1.2.1 Embryonic stem cells 
Embryonic stem cells (ESCs) are isolated from the ICM of the preimplantation 
blastocyst embryo (Figure 1.1). These unique stem cells keep the feature of 
pluripotency from their original fetal cells even after extended manipulation and 
propagation in vitro. ICM gene markers, such as Oct4 (Okamoto et al., 1990), Sox2 
(Avilion et al., 2003), Nanog (Mitsui et al., 2003), Klf4 (Guo et al., 2010), Pecam1 
(Robson et al., 2001), Rex1 (Pelton et al., 2002) and Stella (Sato et al., 2002), are 
highly expressed in ESCs (Tang et al., 2010). When transferred to the mouse 
blastocyst, they incorporate to ICM and generate mice that are chimeric in somatic and 
germ cells (Bradley et al., 1984).  
Initially, mouse ESCs were isolated and cultured on layers of mitotically 
inactivated mouse embryonic fibroblasts (MEFs) called feeders (Evans and Kaufman, 
1981; Martin, 1981). Later it was found that leukaemic inhibitory factor (LIF) is 
secreted by the MEF feeders which suppresses differentiation (Gearing et al., 1987; 
Smith et al., 1988). It has been discovered that the self-renewal and the potency of 
multilineage differentiation can be preserved without MEF feeder in the condition 
with fetal calf serum (FCS) and LIF (Smith et al., 1988). This culture condition is not 
only able to maintain the established ESC lines but also the generation of new 
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germline-transmissible ESC lines from ICM (Nichols et al., 1990; Smith et al., 1988). 
A serum-free culture condition containing LIF and bone morphogenetic proteins 4 
(BMP4) was also demonstrated to sustain self-renewal of ESCs (Ying et al., 2003a). 
This defined culture condition also supports the generation of germline-transmissible 
ESC lines.  
In the last two decades, the discovery of genetic manipulation by homologous 
recombination in ESCs has revolutionized the field of mouse genetics and allows the 
analysis of complicated function of genes in vivo. The ability of germline transmission 
means that mouse ESCs can be served as vehicles for transgenic manipulation. 
Actually one common use of ESCs is the production of mice that carry the 
predetermined genetic modification generated by homologous recombination or gene 
targeting. The designed genetic mutations of ESCs are first generated in cell culture. 
The ESCs with genetic modification are injected into the mouse blastocysts. They 
contribute the differentiated progeny to the recipient and result in the birth of chimeric 
offspring carrying the desired genetic mutation after germline transmission. This 
genetic modification can now be designed in a more complex strategy such that the 
expression of the mutated gene can be spatially or temporally regulated by cell- or 
tissue-specific regulatory elements or the Cre/loxP system (Nagy, 2000).   
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The prospect of ESCs in regenerative medicine has sparked much interest in 
public and scientific communities. ESCs provide a powerful system to identify the key 
determinants of cell fate specification and model the embryonic development through 
the combination of genetic manipulation and in vitro differentiation. Furthermore, 
ESCs can be used to model diseases, conduct toxicity tests, or screening for potentially 
therapeutic compounds. The capability of generating unlimited number of 
differentiated cells makes human ESCs a candidate for cell transplantation. In addition 
to replacing the lost cell, ESCs can also be used as vehicles carrying therapeutic genes 
or drugs while simultaneously serving as donor cells for transplantation.  A major 
concern with the use of ESCs for therapeutic purposes is their potential to form 
teratomas in vivo.  
 
1.2.2 Embryonic carcinoma cells 
The study of embryonic carcinoma cells (ECCs) commences the field of 
pluripotent stem cells. ECCs are derived from teratocarcinomas, which are malignant 
germ cell tumors that contain a differentiated component including all three germ 
layers and another undifferentiated ECC component. A single ECC is capable of 
unlimited self-renewal and multilineage differentiation, providing the intellectual 
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model for the later investigation of ESCs (Kleinsmith and Pierce, 1964). ECCs express 
antigens and proteins similar to ICM cells (Gachelin et al., 1977). Although it has been 
shown that some ECC lines contribute to various somatic cell types upon blastocyst 
injection (Brinster, 1974), most ECC lines poorly contribute to chimeria. The 
accumulation of genetic mutations during teratocarcinoma formation and growth may 
lead to this limited developmental potential (Atkin et al., 1974). 
 
1.2.3 Embryonic germ cells 
Embryonic germ cells (EGCs) are derived from primordial germ cell, which 
migrate from the base of allantois to bilateral genital ridge and eventually give rise to 
new germ cells (Matsui et al., 1992; Resnick et al., 1992). Similar to ESCs, EGCs can 
proliferate indefinitely and contribute extensively to chimeric mice including germ 
cells (Labosky et al., 1994; Stewart et al., 1994). In culture, EGCs are morphologically 
indistinct from ESCs and express ESC markers such as SSEA1 and Oct4. However, the 
derivation of EGCs requires a combination of Steel Factor, LIF and fibroblast growth 
factor (FGF) in the presence of feeder layer (Matsui et al., 1992; Resnick et al., 1992). 
EGCs retain some features of primordial germ cells, including genome-wide 
demethylation, erasure of genomic imprinting and reactivation of X-chromosome, 
which reflects the developmental stages of primordial germ cells (Labosky et al., 1994; 
22
Shovlin et al., 2008; Tada et al., 1997).  
 
1.2.4 Epiblast stem cells 
Epiblast stem cells (EpiSCs) can be derived from postimplantation epiblast of 
mouse or rat in FGF2 on feeders or feeder-free with FGF2 and Activin (Figure 1.1) 
(Brons et al., 2007; Tesar et al., 2007). These cells express core pluripotent markers, 
such as Oct4, Sox2, and Nanog, maintain their genomic integrity, and are competent to 
differentiate into various cell types in vitro (Brons et al., 2007; Tesar et al., 2007). 
However, the self-renewal of EpiSCs relies on Activin instead of LIF pathway (Tesar et 
al., 2007). Marker genes of postimplantation epiblast or early lineage genes, such as 
Pitx2 (Mitiku and Baker, 2007), Brachyury (Mitiku and Baker, 2007), Gata6 (Cai et al., 
2008), Nodal (Morkel et al., 2003), Otx2 (Acampora et al., 1995), Foxa2 (Monaghan et 
al., 1993) and Fgf5 (Hebert et al., 1991), are expressed in EpiSCs (Brons et al., 2007; 
Tesar et al., 2007). Furthermore, EpiSCs are not able to contribute to blastocyst 
chimeras and, therefore, functionally distinct from ESCs. 
 
1.2.5 Induced pluripotent stem cells  
Stem cell-based therapies have attracted much attention regarding the potential 
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as promising donor sources for cell replacement therapies. However, most potential 
sources of cell therapeutics, such as ESCs and tissue specific stem cells, are 
associated with ethical controversy or present technical limitations. Tissue rejection is 
another significant concern for allotransplantation of stem cells. The recent 
establishments of induced pluripotent stem cell (iPSC) presents an exciting prospect 
for autologous cell based therapy and disease modeling.  
iPSC technology is a method for generating pluripotent cells from various somatic 
cell types by introducing defined transcription factors. The first set of reprogramming 
factors are Oct4, Sox2, Klf4 and c-Myc (Figure 1.1) (Takahashi and Yamanaka, 2006). 
iPSCs express a large number of pluripotent markers. Microarray analysis of the global 
gene expression shows remarkable similarity between iPSCs and ESCs (Okita et al., 
2007; Wernig et al., 2007). Epigenetically, iPSCs share with ESCs a bivalent pattern of 
histone trimethylation on histone 3 lysine 4 (H3K4Me3), which is associated with 
transcribed genes, and on histone 3 lysine 27 (H3K27Me3), which is associated with 
silenced genes (Bernstein et al., 2006; Maherali et al., 2007). Sustained by LIF for 
self-renewal (Silva et al., 2008; Takahashi and Yamanaka, 2006), mouse iPSCs exhibit 
functional properties similar to ESCs of mice. They can undergo multi-lineage 
differentiation in the form of embryoid bodies (EBs), teratomas, as well as colonizing 
germline competent chimeras (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 
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2007). After the first successful reprogramming of skin fibroblasts, a number of cell 
types, including stomach cells (Aoi et al., 2008), liver cells (Aoi et al., 2008), pancreatic 
beta cells (Stadtfeld et al., 2008), lymphocytes (Hanna et al., 2008), and neural 
progenitor cells (Kim et al., 2009; Kim et al., 2008; Silva et al., 2008), have been 
reprogrammed.  
 
1.2.6 Early primitive ectoderm-like cells 
Early primitive ectoderm-like cells (EPLCs) are derived from mouse ESCs 
cultured in HepG2 cell-conditioned medium, MEDII (Rathjen et al., 1999). Similar to 
ESCs, EPLCs express the pluripotent markers Oct4, SSEA1 and alkaline phosphatase 
(AP). However, EPLCs express low level of Rex1 but high level of Fgf5. They are not 
able to contribute to chimeric mice unless reverted in medium containing LIF. These 
features suggest that EPLCs are likely counterpart to the cells of postimplantation 
epiblast. It is still unclear whether EPLCs and EpiSCs are identical cell population.  
  
1.2.7 FAB stem cells 
A variation of the pluripotent stem cell line has recently been reported and termed 
as FAB stem cells (FAB-SCs) (Chou et al., 2008). These cells were derived from mouse 
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blastocyst in the medium containing FGF2, Activin and BIO (FAB medium), which is 
also used to derive EpiSCs from postimplantation epiblast. It has been shown that 
FAB-SCs are functionally and molecularly different from both ESCs and EpiSCs. 
FAB-SCs expressed common pluripotent markers, Oct4, Nanog, and Sox2, but are 
unable to form EBs, teratoma or appropriately integrate to ICM after blastocyst 
injection. A brief exposure of FAB-SCs to LIF and BMP4 in the defined medium 
induces the ability to generate teratomas and germline-transmissible chimeric mice 
(Chou et al., 2008).  
 
1.3 Factors controlling pluripotency 
Pluripotency is maintained during self-renewal of pluripotent stem cells through 
promoting proliferation and preventing differentiation. A self-organizing network of 
signalling pathways and transcription factors that maintain pluripotency has been 
revealed. 
 
1.3.1 Signalling pathways regulating pluripotency 
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1.3.1.1 LIF/STAT3 
LIF belongs to the interleukin-6 family and is a key factor of ESCs pluripotency. 
In the presence of LIF, mouse ESCs can be cultured without MEF feeder cells (Smith et 
al., 1988; Williams et al., 1988). The receptor for LIF is a heteromeric complex 
consisting of two transmembrane proteins: gp130 and the LIF receptor (LIFR) (Figure 
1.2A) (Ernst and Jenkins, 2004). The intracellular domain of LIF receptor complex 
constitutively binds to the tyrosine kinase Janus kinase (JAK) (Ernst and Jenkins, 2004). 
After LIF binds to its receptor, JAK phosphorylates both gp130 and LIFR. The 
phosphorylated gp130 and LIFR recruits signal transducers and activators of 
transcription 3 (STAT3) (Stahl et al., 1995). STAT3 are subsequently phosphorylated 
and activated by JAK. The phosphorylated STAT3 form dimers and translocate into the 
nucleus (Auernhammer and Melmed, 2000). It has been shown that STAT3 is essential 
for maintaining the self-renewal of mouse ESCs (Niwa et al., 1998). The activation of 
STAT3 is sufficient for their self-renewal in the absence of LIF (Matsuda et al., 1999). 
However, in serum-free condition, LIF alone is not sufficient in blocking 
differentiation and requires BMP4 to preserve self-renewal of mouse ESCs (Ying et al., 
2003a). 
One of the important target genes of STAT3, c-Myc, is an regulator of the cell 
cycle (Luscher and Eisenman, 1990). It acts via activating the expression of cyclin E 
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and promoting G1-S transition (Hooker and Hurlin, 2006). Forced expression of a 
dominant-active form of c-Myc has greater ability of stabilization of self-renewal of 
mouse ESCs than the wild-type protein independent to LIF (Cartwright et al., 2005). By 
contrast, forced expression of a dominant-negative form of c-Myc disturbs self-renewal 
of ESCs and promotes their differentiation (Cartwright et al., 2005). These findings 
suggest that LIF signalling pathway promotes self-renewal of mouse ESC by regulating 
G1-S transition via c-Myc (Burdon et al., 2002). 
 
1.3.1.2 BMP/Smad1/5/8 
BMPs are members of the transforming growth factor β superfamily, (Shi and 
Massague, 2003). These secreted proteins form complex with receptor components by 
binding to type I and type II BMP receptors and facilitates phosphorylation of 
Smad1/5/8 (Figure 1.2B). The phosphorylated Smads bind to Smad4, and then 
translocate to the nucleus and function as transcription factors (Murakami et al., 2003). 
The activated Smad complex induces the expression of inhibitor of differentiation (Id), 
which is known to be involved in many cell fate determination (Ying et al., 2003a). The 
combination of LIF with either BMP4 or overexpression of Id is able to maintain 
self-renewal of mouse ESCs. By contrast, BMP4 alone induces non-neural 
differentiation of mouse ESCs. These findings suggest that a delicate balance between 
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LIF and BMP is required for maintaining self-renewal of ESCs (Ying et al., 2003a).  
 
1.3.1.3 Activin/Smad2/3 
Activin is also a member of transforming growth factor β superfamily, and is 
required to maintain pluripotency of EpiSCs (Brons et al., 2007; Tesar et al., 2007; 
Vallier et al., 2005). Activin binds to heteromeric complexes between type 1 and type II 
Activin receptors, which facilitate the phosphorylation and activation of Smad2/3 
(Figure 1.2C). It has been shown that Activin signalling controls expression of Nanog 
in EpiSCs (Greber et al., 2010; Vallier et al., 2009). In turn, Nanog may block the 
endodermal differentiation by modulating the activity of Smad/2/3 (Vallier et al., 2009). 
This negative feedback loop seems to maintain the undifferentiation of EpiSCs.  
 
1.3.1.4 FGF 
FGF is one of the important factors for the maintenance of EpiSC self-renewal 
(Brons et al., 2007; Tesar et al., 2007). FGF binds to its receptor, a receptor tyrosine 
kinase, which in turn activates phosphotidyl inositol 3 kinase (PI3K)/Akt and 
mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) 
pathways (Figure 1.2D). The PI3K/Akt pathway has been shown to be important in the 
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maintenance of pluripotency of mouse ESCs (Takahashi et al., 2005). Forced 
expression of dominant-negative form of PI3K or the addition of LY294002, a PI3K 
inhibitor, induces their differentiation (Paling et al., 2004). Forced expression of the 
active form of Akt is able to maintain the self-renewal of mouse ESCs (Watanabe et al., 
2006). The MAPK/ERK pathway also plays an important role in the promotion of 
differentiation and suppression of proliferation of ESCs (Kunath et al., 2007). The 
addition of PD98059, a MAPK inhibitor, efficiently promotes the derivation of mouse 
ESCs from ICM (Burdon et al., 1999). The endogenous MAPK/ERK activity existing 
in mouse ESCs creates a tendency of neural differentiation (Stavridis et al., 2007; Ying 
et al., 2003b).  
 
1.3.1.5 WNT/β-Catenin 
The canonical Wingless/Int (WNT) pathway signals through β-Catenin (Reya and 
Clevers, 2005). In an absence of WNT activation, β-Catenin is phosphorylated by a 
complex composed of Glycogen Synthase Kinase-3β (GSK-3β), Adenomatosis 
polyposis complex (APC) and Axin. Phosphorylated β-Catenin is degraded by the 
ubiquitin-proteosome system. In contrast, when WNT binds to its receptor, GSK-3β is 
inactivated, leading to accumulation of β-Catenin and translocates to the nucleus 
(Figure 1.2E). In the nucleus, β-Catenin acts as a transcription factor and activates a 
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series of genes including Oct4, Nanog, Id and Stat3 (Aubert et al., 2002; Hao et al., 
2006; Sato et al., 2004).  
It has been shown that overexpression of WNT1 or addition of lithium chloride, a 
GSK-3β inhibitor, can suppress neural differentiation of mouse ESCs (Aubert et al., 
2002). 6-Bromoindirubin-3’- oxime (BIO), another chemical inhibitor of GSK-3β, 
maintains the expression of Oct4, Rex1, and Nanog and self-renewal of mouse ESCs in 
the absence of LIF (Sato et al., 2004).  
 
1.3.2 Transcription factors for the maintenance of pluripotency 
    The maintenance of pluripotency requires the expression of transcription factors 
Oct4, Sox2, Klf4 and Nanog. These factors have an influence on the expression of other 
transcription factors, and form a network to determine the pluripotency.  
 
1.3.2.1 Oct4 
Oct4 is identified as an Oct family protein specifically expressed in ICM, 
postimplantation epiblast, and germ cells (Okamoto et al., 1990; Rosner et al., 1990; 
Scholer et al., 1990). It is also expressed in pluripotent stem cells, including ESCs and 
EpiSCs (Brons et al., 2007; Rosner et al., 1990; Tesar et al., 2007). Oct4 knockout 
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embryos die before implantation and were unable to reach the blastocyst stage (Nichols 
et al., 1998). Oct4 is required for somatic cell reprogramming (Kim et al., 2009). In 
mouse ESCs, the suppression of Oct4 results in spontaneous differentiation into 
trophoblast lineages (Niwa et al., 2000). By contrast, a 50% increase of Oct4 protein 
level in mouse ESCs is sufficient to induce differentiation into primitive endoderm and 
mesoderm (Niwa et al., 2000). These studies show that the the expression level of Oct4 
is a critical determinant of pluripotency. 
 
1.3.2.2 Sox2 
Sox2, a Sox (SRY-related HMG box) protein, is expressed in the ICM, epiblast, 
and germ cells (Avilion et al., 2003). In addition, Sox2 is also expressed by the 
uncommitted mitotic neural precursors of the developing central nervous system 
(Avilion et al., 2003; Li et al., 1998). Sox2 knockout embryos die during implantation 
due to failed epiblast development (Avilion et al., 2003). Homozygous mutant mouse 
blastocysts appear morphologically normal, but fail to generate of ESCs in vitro 
(Avilion et al., 2003). Sox2 is indispensible for reprogramming from fibroblasts 
(Takahashi and Yamanaka, 2006). The deletion of Sox2 in ESCs induces 
trophectoderm differentiation (Masui et al., 2007). Therefore, Sox2, like Oct4, is 
essential for the maintenance of pluripotency. 
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Sox2 forms a heterodimer with Oct4 to keep the expression of other genes 
involved in the maintenance of pluripotency (Nishimoto et al., 2003; Tokuzawa et al., 
2003; Yuan et al., 1995). Sox2/Oct4 dimer regulates the expression of Sox2, Oct4 and 
Nanog, and shares many regulatory targets with Sox2, Oct4 and Nanog proteins 
(Boyer et al., 2005; Chew et al., 2005; Kuroda et al., 2005). Interestingly, the 
introduction of either Sox2 or Oct4 rescue Sox2-deficient ESC, suggesting a 
requirement for Sox2 in the maintenance of Oct4 expression (Masui et al., 2007). 
 
1.3.2.3 Nanog 
Nanog is a homeodomain-containing protein and is essential for early embryonic 
development. It also plays an important role in the transcriptional network of 
pluripotency. The expression of Nanog is mainly in ICM, epiblast and germ cells. 
Forced expression of Nanog enables LIF-independent self-renewal of mouse ESCs 
(Chambers et al., 2003). In Nanog knockout mouse the mutant blastocysts develop ICM 
that collapse after implantation (Mitsui et al., 2003).  
Interestingly, Nanog is not one of the essential transcription factors involved in 
reprogramming mouse and human somatic cells (Maherali et al., 2007; Okita et al., 
2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007). 
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The reprogramming efficiency has not been increased by the addition of Nanog to the 
transcription factor combinations. Nanog knockout ESCs can be maintained 
indefinitely and contribute to chimeras, albeit they are biased toward differentiation 
(Chambers et al., 2007). On the other hand, expression of Nanog is weak or absent in 
the partial reprogrammed cells that are unable to properly activate the pluripotent 
transcriptional circuitry (Silva et al., 2008; Sridharan et al., 2009; Takahashi and 
Yamanaka, 2006). Selection with endogenous Nanog expression improves the isolation 
of mouse iPSCs that are fully reprogrammed (Okita et al., 2007). In the process of 
reprogramming, Nanog is essential for the transition from pre-pluripotent intermediates 
to truely pluripotent cells (Silva et al., 2009). These findings establish a central role of 
Nanog in the acquisition of pluripotency in the final stage of somatic cell 
reprogramming.  
 
1.3.2.4 Klf4 
Klf4 belongs to Kruppel-like factors and is highly expressed in ESCs (Guo et al., 
2009; Jiang et al., 2008). Klf4 knockout embryos develop normally, but newborn mice 
die within 15 hours and show an impaired differentiation of epidermis and goblet cells 
in the colon (Katz et al., 2002; Segre et al., 1999). It seems that Klf4 is a downstream 
target of LIF signalling pathway. Inactivation of STAT3 in mouse ESCs attenuates the 
34
expression of Klf4. Similar to Nanog, forced expression of Klf4 is able to support 
LIF-independent self-renewal of mouse ESCs (Niwa et al., 2009). Although Klf4 
knockdown ESCs do not present morphological changes, the triple knockdown of Klf2, 
Klf4 and Klf5 reduce the expression of Nanog in ESC (Jiang et al., 2008). In addition 
to be part of the canonical quartet transcription factors for somatic cell 
reprogramming, Klf4 itself is able to reprogram EpiSCs to ground state pluripotency 
(Guo et al., 2009). These findings demonstrate a crucial role for Klf4 in the 
maintenance of pluripotency and reprogramming.  
 
1.4 Histone modification pattern of pluripotent stem cells 
Histone modification pattern has been shown to regulate gene expression of 
pluripotent stem cells. In mouse ESCs and EpiSCS, pluripotent genes are associated 
with the abundance of methylated histone H3 lysine 4 (H3K4), a marker of gene 
induction (Azuara et al., 2006; Tesar et al., 2007). In contrast, abundant methylated 
histone H3 lysine 27 (H3K27), a marker of gene repression, is seen in a few silenced 
gene loci in mouse ESCs and EpiSCs (Azuara et al., 2006; Tesar et al., 2007). In 
pluripotent stem cells, both activating and repressive histone modifications are detected 
in a number of silenced genes that are critical for cell lineage determination, such as Sox, 
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Hox, Pax, and Pou gene families, (Azuara et al., 2006; Bernstein et al., 2006). This 
unique histone modification pattern for silencing the lineage-control genes is termed as 
“bivalent” histone modifications. During the differentiation from mouse ESCs, these 
bivalent histone modification patterns resolved. In neural precursors derived from 
ESCs, the promoters of bivalent genes that are markedly induced during neural 
differentiation became preferentially associated with inductive mark H3K4 and lost the 
repressive mark methylated H3K27 (Bernstein et al., 2006). In contrast, the promoters 
of bivalent genes that remain silent in neural precursors lost the methylated H3K4 and 
retained the abundance of methylated H3K27 (Bernstein et al., 2006). Otx2, a bivalent 
gene in mouse ESCs, had solely H3K4Me3 but lost H3K27Me3 in EpiSCs (Tesar et al., 
2007). These studies suggest that these bivalent genes are situated in a relatively 
permissive chromatin conformation maintained by the balance between methylation of 
H3K4 and H3K27. This permissive chromatin conformation in ESCs makes these 
genes easy to get to chromatin remodeling complexes for subsequent transcriptional 
initiation in response to appropriate differentiation condition. The repressive histone 
modifications would be removed from the loci of key lineage-control bivalent genes 
and the activating modifications would be maintained while ESCs are differentiated 
into a specific lineage. In contrast, activating histone modification of the loci of 
unnecessary, silent bivalent genes would be removed while the repressive modification 
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would be maintained during differentiation. However, a number of key developmental 
genes in ESCs do not show bivalent histone modifications but still accessible for 
activation at later developmental stages, suggesting the presence of other regulatory 
mechanisms of gene expression.  
 
1.5 Multiple interchangible pluripotent states  
The pluripotent cell entity in embryo seems to be heterogeneous. Although nearly 
all the cells in ICM express Oct4, only a proportion express Nanog (Chazaud et al., 
2006). The same heterogeneity is presented in ESC population. Nanog is expressed in 
only 80% of mouse ESCs cultured in serum-LIF (Chambers et al., 2007). Although 
Nanog- ESCs can efficiently contribute to chimera, these cells form greater number of 
differentiated colonies than Nanog+ ESCs when plated at clonal density in serum-LIF. 
This suggests that Nanog- ESCs are predisposed to differentiation. Isolated Nanog- 
ESCs reestablish the Nanog+ ESC population in seven days in culture. Similar 
heterogeneity and interchangeability can be seen in ESC population using other 
markers. Rex1 is expressed in 90% of mouse ESCs (Toyooka et al., 2008). Rex1+ ESCs 
integrate to chimera efficiently, while Rex1- ESCs are unable to form chimera. On the 
other hand, Rex1- ESCs differentiated into cells of somatic lineages more efficiently 
than non-fractionated ESCs. A purified Rex1+ population generates a Rex1- population, 
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and reversely a Rex1+ population can emerge from a purified Rex1- population within 
five days of culture. By analyzing the characteristics of Stella+ and Stella- cells in 
mouse ESCs, Hayashi et al showed that these two populations have different gene 
expression pattern and remarkable functional differences (Hayashi et al., 2008). Stella+ 
cells are enriched in ICM specific markers Pecam1 and Rex1, deprived of epiblast 
marker Fgf5, and capable to form EBs. By contrast, the Stella- cells express lower 
levels of Pecam1 and Rex1, are enriched of Fgf5, and seldom form EBs. Compared to 
Stella+ cells, Stella- cells show an accelerated neuronal differentiation potential with the 
treatment of RA. It remains unclear whether the Nanog-, Rex1- and stella- cells are 
distinct. Nevertheless, these studies propose that ESCs in serum-LIF are heterogeneous 
and exist in interchangeable pluripotent state(s).   
Recently, Bao et al demonstrated a reversion of pluripotent state from EpiSCs to 
ESCs (Bao et al., 2009). In serum-LIF, EpiSCs gradually loss epiblast markers and 
acquired ICM marker expression. With further passaging, these cells regain the ability 
to colonize chimeras, suggesting they are converted to the ground state similar to ESCs. 
This continuing reversion supports the existence of an intermediate cell state between 
ESCs and EpiSCs. 
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1.6 Aims  
The notion of an intermediate cell state within pluripotent stem cells refines the 
understanding of pluripotent state, and raises interesting questions that I aim to address 
in this thesis: 
1, Can an intermediate stem cell state be captured as stable clonogenic cell lines? 
2, What is the signalling pathway these intermediate stem cells use for self-renewal? 
3, What is the molecular make up of intermediate stem cells and how these features 
affect their responsiveness to culture environmental factors?  
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Figure 1.1 Derivation of pluripotent stem cells 
Pluripotent stem cells can be derived from embryos of different development stage. 
Mouse ESCs are generated from ICM of preimplantation embryos, whereas Activin 
and FGF2 support the establishment of EpiSCs from postimplantation epiblast 
Transduction of transcription factors (Oct4, Sox2, Klf4 and c-Myc) reprograms 
somatic cells to iPSCs, which are functionally the same as mouse ESCs.   
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Figure 1.2 Signalling pathways controlling pluripotency 
The signalling pathways controlling pluripotent stem cell self-renewal. (A) 
Intracellular signalling activated by LIF. Binding of LIF with its receptor, which 
consists of LIFR and gp130, results in the activation of JAK and phosphorylation of 
STAT3. The phosphorylated STAT3 regulates gene transcription. LIF/STAT3 pathway 
is crucial for the self-renewal in mouse ESCs. (B) Intracellular signalling activated by 
BMP. Binding of BMP to the receptor complex composed of type I and type II BMP 
receptors induces phosphorylation of Smad1/5/8. Phosphorylated Smad1/5/8 forms 
complexes with Smad4 and accumulate in the nucleus, where together they regulate 
gene transcription. BMP4 can support the self-renewal of mouse ESCs in combination 
with LIF. (C) Intracellular signalling activated by Activin. Type I and type II Activin 
receptors form a complex. Binding of Activin to this complex leads to phosphorylation 
of Smad2/3. The association of phosphorylated Smad2/3 with Smad4 controls gene 
transcription. The activation of Activin/Smad2/3 pathway is critical for the 
self-renewal of EpiSCs. A small molecule SB431542 can inhibit Activin/Smad2/3 
signalling by blocking the phosphorylation of Smad2/3.  (D) Intracellular signalling 
activated by FGF. Binding of FGFs to their receptors activates PI3K/Akt and 
MAPK/ERK pathways. The PI3K/Akt pathway promotes self-renewal of mouse ESCs, 
while MAPK/ERK pathway induces differentiation in mouse ESCs. MAPK/ERK 
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pathway can be inhibited by a small molecule PD0325901. (E) Intracellular signalling 
activated by WNT. After binding to its receptor, WNT inactivates the 
APC/Axin/GSK-3β complex. Since this complex induces phosphorylation and 
degradation of β-catenin in the absence of WNT ligand, its inactivation results in the 
stabilization and accumulation of β-catenin, which controls gene expression. In mouse 
ESCs, the WNT/β-catenin pathway promotes their self-renewal. GSK-3β inhibitors 
CHIR99021 and BIO inhibit the phosphorylation of β-catenin and activates 
WNT/β-Catenin pathway. The combination of CHIR99021, PD0325901 and LIF 
(2i-LIF) can keep the self-renewal of mouse ESCs.
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Chapter 2 Materials and Methods 
 
2.1 Materials 
Unless otherwise stated, all analytical grade chemicals were supplied by Sigma or 
BDH laboratory. Stock solutions were prepared with reverse osmosis water and filtered 
or autoclaved as necessary. Agarose for electrophoresis was obtained from Invitrogen. 
Synthetic oligonucleotides were synthesized by Sigma. Mice were supplied from 
Charles River.  
 
2.1.1 Solutions  
Phosphate buffered saline (PBS):  
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4.7H2O, 1.4mM KH2PO4 (pH 7.4)  
 
PBST:  
0.3% (v/v) Triton X-100 in PBS  
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1X TAE:  
0.04M Tris-acetate, 0.001M EDTA  
 
Luria-Bertani (LB) broth:  
1% (w/v) tryptone (Difco), 0.5% (w/v) yeast extract, 85mM NaCl  
 
LB agar:  
1.5% (w/v) agar (Difco) in LB broth 
 
Lysis buffer:  
10mM Tris (pH 8.0), 50mM EDTA, 100mM NaCl, 0.5% sodium dodecyl sulfate 
(SDS)  
 
Running buffer: 
5mM Tris, 192mM glycine (Fisher), and 0.1% SDS 
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Transfer buffer: 
25mM Tris, 192mM glycine, 20% methanol, and 0.037% SDS 
 
ChIP lysis buffer: 
0.1% Triton X-100 and 0.4mM PMSF (Sigma) in PBS 
  
MA buffer: 
0.25M Sucrose, 3mM MgCl2, 10mM Tris-acetate pH 8.0 
 
ChIP resuspension buffer: 
4ml MA, 1ml 5☓ Complete Protease Inhibitor Cocktail (Roche), 2mM CaCl2 
 
ChIP dilution buffer: 
200mM NaCl, 1mM EDTA, 1% Triton X-100, 20mM Tris-acetate pH 8.0 
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ChIP elution buffer: 
0.1M NaHCO3, 1% SDS 
 
2.1.2 Medium for cell culture 
 
GMEM/FCS medium 
1X Glasgow minimum essential medium (GMEM, Invitrogen), 10% (v/v) fetal calf 
serum (FCS, BioSera), 1mM sodium pyruvate (Invitrogen), 1☓ MEM non-essential 
amino acid (Invitrogen), 2mM l-glutamine (Invitrogen), 0.1mM 2-mercaptoethanol 
(Invitrogen) 
 
N2B27 medium 
1:1 mixture of DMEM/F12 (Invitrogen) supplemented with modified N2 (25μg/ml 
insulin, 100μg/ml apotransferrin, 6ng/ml progesterone, 16μg/ml putrescine, 30nM 
sodium selenite, 50μg/ml bovine serum albumin, Invitrogen) and Neurobasal medium 
(Invitrogen) supplemented with B27 (Invitrogen). 
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FAB medium 
Dulbecco’s Modified Eagle Medium, 15% Knock Out Serum Replacement 
(Invitrogen), 1mM sodium pyruvate, 2mM l-glutamine, 1X non-essential amino acids, 
0.1mM 2-mercaptoethanol, 50μg/ml ascorbic acid (Sigma), 100μg/ml iron-saturated 
transferrin (Sigma), 1ng/ml FGF2 (Peprotech), 0.5μM BIO (Sigma) and 50ng/ml 
Activin A (R&D).  
 
2.2 Molecular biology methods 
 
2.2.1 Transformation of competent cells 
A 50μl aliquot of DH5α competent cells (Invitrogen) was thawed on ice. After 
adding approximately 10ng of plasmid DNA, the competent cells were gently stirred 
and placed on ice for 30 minutes. The mixture was then heat-shocked for 20 seconds at 
42°C and immediately placed on ice for 2 minutes. 1ml of LB broth was added and the 
tube was incubated in an automated shaker (Sorvall) for 1 hour at 37°C. 50 to 300μl of 
the mixture were plated on LB agar plates with appropriate antibiotics and incubated 
for overnight at 37°C.  
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2.2.2 Amplification of transformed bacterial colonies 
Single colonies from the agar plates were picked using a 200μl plastic pipette tip 
(Star Lab) and transferred to a 15ml Falcon tube (Marathon) containing 10ml of LB 
broth with selection drug. After overnight incubation in an automated shaker at 
225-250rpm at 37°C, the bacterial suspensions were used for mini or maxi-prep 
(Qiagen). 
 
2.2.3 Preparation of plasmid DNA 
To prepare desired quantities of plasmid DNA, Qiagen mini-prep kits were used 
according to manufacturer’s instructions. 1ml of the bacterial suspension was 
transferred to a clean 1.5ml Eppendorf tube (Star Lab), centrifuged in an Eppendorf 
5415R centrifuge at 13000rpm for 3 minutes and the supernatant was discarded. 150μl 
of solution I was added to the tube and it was vortexed by VM20 vortex mixer (Chiltern 
Scientific) to mix well. To lyse the cells, 150μl of solution II was added and the tube 
was inverted 4-5 times to mix. 250μl of cold solution III was added to neutralize the 
lysate and the tube was inverted 4-5 times to mix. The sample was then centrifuged at 
13000rpm for 15 minutes and the supernatant transferred to a clean tube. To precipitate 
the DNA, 1ml of cold ethanol was added and the tube was inverted 4-5 times to mix 
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before incubating at -20ºC for 30 minutes. The sample was then centrifuged at 
13000rpm for 30 minutes to pellet the DNA, which was then dissolved in 50μl dH2O to 
give a final concentration of about 2.5μg/ml.  
 
2.2.4 Extraction and purification of RNAs 
Cells cultured in 9cm diameter Petri dish (Nunc) were lysed and homogenized in 
500μl Tri-reagent (Sigma). The lysate was transferred to a clean 1.5ml Eppendorff tube 
and incubated for 5 minutes at room temperature. To extract RNA, 200μl chloroform 
was added and the tube shaked vigorously for 15 seconds. The tube was centrifuged at 
12000rpm for 15 minutes at 4°C. The aqueous phase was collected in a clean 1.5ml 
Eppendorf tube. To precipitate RNA, 500μl isopropanol was added and the tube was 
incubated for 10 minutes at room temperature. The tube was centrifuged at 12000rpm 
for 10 minutes at 4°C and the suspension was removed. 1ml 75% ethanol was added to 
wash RNA pellet. After centrifuged at 12000rpm for 5 minutes at 4°C, the pellet was 
air-dried for 10 minutes and dissolved in 30μl RNAase-free water. Purified RNA was 
quantified using NanoDrop ND-1000 (Labtech). 
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2.2.5 Reverse transcription 
To generate cDNA from purified RNA, 1μg of total RNA was mixed with 1μl 
Random Hexamers (3μg/μl, Invitrogen), 1μl dNTP mix (10mM, Invitrogen) and 
appropriate amount of water to the volume of 13μl in a thin wall PCR tube (Fisher). The 
tube was heated to 65°C for 5 minutes, and then incubated on ice for one minute. 4μl 
5X first strand buffer (Invitrogen), 1μl 0.1M DTT, 1μl RNAguard RNAase inhibitor 
(27600u/ml, Amersham Bioscience) and 2μl Superscript III reverse transcriptase 
(200u/μl, Invitrogen) were added and the tube was incubated for 5 minutes at 25°C, 
then for 60 minutes at 55°C and finally for 15 minutes at 70°C. To remove the 
remaining of RNA, 1μl RNase H (2u/μl, Invitrogen) was added and the tube was 
incubated for 20 minutes at 37°C. The cDNA was diluted 1:10 in water and the diluted 
cDNA was used for quantitative polymerase chain reaction (Q-PCR). 
 
2.2.6 Quantitative reverse transcription polymerase chain reaction (Q-PCR) 
Q-PCR was performed with MESA GREEN qPCR Mastermix Plus (Eurogenetec) 
and analyzed with the Chromo 4 real-time PCR system (Bio-rad). Briefly, 2μl 1:10 
diluted cDNA was mixed with 10μl SYBRGreen PCR mix (Bio-rad), 10μM forward 
primer, 10μM reverse primer and 6μl water. The amplification was done for 40 cycles 
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(94° 1 min, 65° 1 min, 72° 1 min). To verify the PCR product, melting curve was 
carried out in each reaction. Q-PCR was performed in triplicates. Each set of values 
was expressed as means ± standard deviation. 
 
2.2.6.1 List of gene specific primers for Q-PCR: 
Genes Forward Reverse 
Afp tttccagaacctgccgagag gagcagccaaggacagaatg 
β-actin ggttacaggaagtccctcacc tggctgcctcaacacctcaac 
Bmp4 agccgagccaacactgtgag tggaagccctgttcccagtc 
Brachyury aacggcaggaggatgttccc ttccagcggtggttgtcagc 
Esrrb acctgaacctgccgatttcc tgcttggcccagttgatgag 
Fgf5 gcagagtgggcatcggtttc tgtggatcgcggacgcatag 
Foxa2 ctgggagccgtgaagatgga attccagcgcccacatagga 
Gata6 gactcctacttcctcttcttctaattcaga acctgaatacttgaggtcactgttctc 
Goosecoid gcaccatcttcaccgatgag cggcggttcttaaaccagac 
Klf4 agaacagccacccacacttg agtgcctggtcagttcatcg 
Nanog cttacaagggtctgctactgagatgc tgcttcctggcaaggacctt 
Nestin tgagaactctcgcttgcagacac ggtcctctggtatcccaaggaaatg 
Nodal catccagagcctgctgaaac acccacactcctccacaatc 
Oct4 cacgagtggaaagcaactca agatggtggtctggctgaac 
Otx2 taaagcaaccgccttacgc tcctctcccttcgctgtttc 
Pax6 gtcagtgaatgggcggagttatgatacctaca cgggaacttggacgggaactgacactc 
Pecam1 aacagagccagcagtatgag atgacaaccaccgcaatgag 
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Pitx2 gcaacgccggcagaggactcatttcacta ctttctccatttggcccggcgattctt 
Rex1 cgcatcgctgtgggcattag ggcactgatccgcaaacacc 
Socs3 gtcacccacagcaagtttcc tccagtagaatccgctctcc 
Sox2 aacgccttcatggtatggtc ttgctgatctccgagttgtg 
Stella aagttcaaagcgcctttccc tcactgtcccgttcaaactc 
Tuj1 atcagcaaggtgcgtgaggag atggacagggtggcgttgtag 
 
2.2.7 Western blot analysis 
Cells were lysed with lysis buffer. The protein concentration of cell lysate was 
measured by DC protein assay (Bio-Rad). Samples were diluted to the concentration of 
0.7mg/ml with 1%SDS. 12.5µl of each sample was loaded into the well of a 4.3% 
SDS-polyacrylamide stacking gel and separated by electrophoresis on 10% 
SDS-polyacrylamide running gel at 150V for 30-45 minutes in running buffer. The gels 
were then placed in a semi-dry transfer cell (Bio-Rad) in which the nitrocellulous 
membrane (GE healthcare) had been rinsed in transfer buffer. Proteins were transferred 
by running at 15V for 1h in transfer buffer. The membranes were blocked with 3% 
skimmed milk in PBST containing phosphate buffered saline with 0.05% Tween-20 
(Fisher) for 1h at room temperature, and incubated with primary antibody appropriately 
diluted with 3% skimmed milk in PBST at 4°C overnight. After washing with PBST, 
the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary 
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antibody for 1 hr at room temperature. The signals were then detected with enhanced 
chemiluminescence (Roche) and Hyperfilm ECL (GE Healthcare). Primary antibodies 
used for Western Blot were goat anti-Lamin B (1:2000, Santa Cruz), rabbit anti-Nanog 
(1:1000, Abcam), rabbit anti-Smad2/3 (1:1000, Cell signalling), and rabbit 
anti-p-Smad2 (1:1000, Cell signalling). Secondary antibodies were goat anti-rabbit 
IgG-HRP (1:2500, GE healthcare), and donkey anti-goat IgG-HRP (1:2500, Santa 
Cruz). 
 
2.2.8 Chromatin immunoprecipitation 
 
2.2.8.1 Preparation and fragmentation of chromatin 
1×107 cells cultured in 15cm diameter Petri dish (Corning) were crosslinked with 
1% formaldehyde for 10 minutes at room temperature. 20ml ChIP lysis buffer was 
added to the dish. Cells were scraped and transferred to a 50ml Falcon tube (BD 
Biosciences), and then were centrifuged in Eppendorf 5810R centrifuge at 2000rpm for 
5 min at 4°C. The suspension was discarded, and the pellet was resuspended in 500μl 
ChIP resuspension buffer. To fragment chromatin, 0.5μl micrococcal nuclease 
(100u/ml, Roche) was added and the tube was incubated for 5 minutes at room 
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temperature. 25μl 0.5M EDTA, 25μl 20% Triton X-100 and 25μl 20% SDS were added 
to the mixture and the tube was sonicated with Sonics sonicator (Vibra Cell) for 2 
minutes. The lysate was centrifuged at 12000rpm for 15 minutes at 4°C and the DNA 
suspension was transferred to a clean 1.5ml Eppendorff tube. 
 
2.2.8.2 Test of chromatin fragmentation 
1μl RNAaseA (10 mg/ml, Invitrogen) was added to 50μl DNA suspension and the 
tube was incubated for 10 minutes at room temperature. 450 μl ChIP elusion buffer and 
20μl 5 M NaCl were added and the tube was incubated for overnight at 50°C. To purify 
DNA, 500μl phenol/chloroform (1:1 v/v) mixtures were added to the tube and mixed 
vigorously. The tube was centrifuged at 12000rpm for 5 minutes at room temperature. 
The aqueous phase was transferred to a clean Eppendorf tube and incubated for 1 hour 
at -20°C after adding 50μl 3M NaOAc and 500μl isoproponol. The tube was 
centrifuged at 12000rpm for 15 minutes at 4°C and the suspension was removed. The 
DNA pellet was washed with 1ml 75% ethanol and resuspended in 50μl TAE. To check 
DNA fragmentation, 5μl DNA was loaded on 1.5% agarose gel and run at 70V for 1 
hour at room temperature.  
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2.2.8.3 Immunoprecipitation of fragmentized chromatin 
4.5ml ChIP dilution buffer was added to 500μl DNA suspension in a clean 15ml 
Falcon tube and put on ice for 5 minutes. The tube was centrifuged at 12000rpm for 15 
minutes at 4°C. 1ml supernatant (cleared chromatin) was transferred to a clean 1.5ml 
Eppendorf tube and add with 40μl 10mg/ml bovine serum albumin, 40μl salmon sperm 
DNA/protein A agarose (Sigma), and desired amount of antibodies. The tube was 
incubated overnight at 4°C, and then centrifuged at 800rpm for 1 minute at room 
temperature. After carefully removing the supernatant, the agarose beads were washed 
with 1ml ChIP dilution buffer for 3 times and TAE for 2 times. To elute DNA from the 
agarose beads, 500μl ChIP elution buffer was added to the sample. The tube was 
incubated for 15 minutes at room temperature and then centrifuged at 800rpm for 1 
minute at room temperature. 20μl 5M NaCl was added and the tube was incubated for 
overnight at 50°C. To purify DNA, 500μl phenol/chloroform mixtures were added to 
the tube and mixed vigorously. The tube was centrifuged at 12000rpm for 5 minutes at 
room temperature. The aqueous phase was transferred to a clean Eppendorf tube and 
incubated for 1 hour at -20°C after adding 50μl 3M NaOAc and 500μl isoproponol. The 
tube was centrifuged at 12000rpm for 15 minutes at 4°C and the suspension was 
removed. The DNA pellet was washed with 1ml 75% ethanol and resuspended in 100μl 
TAE. The DNA was used for Q-PCR as templates.  
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2.2.8.4 List of antibody for ChIP: 
Antibodies  Amount for ChIP 
Histone H3 (Upstate) 2μl 
Trimethyl Lys 4 histone H3 (07-473, Upstate) 5μl 
anti-trimethyl Lys 27 histone H3 (07-449, Upstate) 2μl 
 
2.2.8.5 List of ChIP Primers for Q-PCR: 
Primers Forward Reverse 
Fgf5-C ggaagcggctcggaacatag gcctgtggcccaaaggaatc 
Fgf5-P caaccgctgggttgcatgac acccgccgctttgtgtactc 
Klf4-C tggacttgggaacagaaagg aaatctacagggcactagcg 
Klf4-P cctttacctcgccgcttcac ggcgcggagatacctttcac 
Myf5-C gattgcttgtccagcattgt agtgatcatcgggagagagtt 
Myf5-P tgctgctgctgctgattatg tggtccctttgacgctaatg 
Nanog-C ggtgttacccaggggtgacaaagt caaagcaattatcttcatagatctaagtaacaag 
Nanog-P ctgggtgcctgggagaatag cagtgtgatggcgagggaag 
Nkx2.2-C agagccctcggctgacgagt cgtgagacggatgaggctgg 
Nkx2.2-P caggttcgtgagtggagccc gcgcggcctcagtttgtaac 
Oct4-C cctgcagaaggagctagaaca tgtggagaagcagctcctaag 
Oct4-P ggctctccagaggatggctgag tcggatgccccatcgca 
Otx2-C tggatctgtagcctcctgac agactagcacagggcttgac  
Otx2-P tcgagagcggtcaccttaac cttctccacagcgagcttag 
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Pecam1-C gcatggccggaagacagaac tcacagagcaccagcgtgag 
Pecam1-P cctgcttccttcttcccttc ttctcctacaccgctgtctc 
Rex1-C taatggtgcccggcgtatttat agcctctcccggaccccgctac 
Rex1-P cgggcggaagagccctcgacag ccagaatgggttcggaaaactcacctcgta 
Stella-C tgaagaggacgctttggatg tgggtttgcactcacaacag 
Stella-P aaggtgtagctcaggtgaag agcagtcagtctgtgaatgg 
 
2.3 Mammalian cell culture.  
Cells were incubated at 37°C with 5% CO2 in a humidified incubator (Sanyo). All 
solutions were sterility tested before use. To avoid bacterial and fungal contamination, 
all tissue culture manipulations were undertaken inside a laminar flow sterile hood 
(Nuaire) and surfaces and objects were sprayed with 70% ethanol before use. 
 
2.3.1 Routine culture of ESCs, iPSCs and ALSCs 
Mouse ESCs and iPSCs were routinely cultured on 0.1% gelatine-coated 25cm2 
tissue culture flasks (Marthon) in GMEM/FCS medium supplemented with 100u/ml 
homemade LIF. Mouse iPSCs were also cultured in N2B27 medium supplemented with 
1μM PD0325901 (PD, Stemgent), 3μM CHIR99021 (Stemgent) and 100u/ml 
homemade LIF. ALSCs were cultured in GMEM/FCS medium supplemented with 
12ng/ml Activin A.  
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For experiments described in Figure 3.9, 3.10 and 3.11, short treatments with 
various factors/chemicals were carried out in N2B27. 1×105 of cells were plated 12 
hours before treatments. The molecules used for short treatment were as follows: 
Activin A: 12ng/ml, JAKI (Calbiochem): 1μM; LIF (Sigma): 10ng/ml; PD0325901: 
1μM, and SB431542 (SB, Sigma): 10μM. 
 
2.3.2 Passaging ESCs, iPSCs and ALSCs 
To dissociate the cells, 0.025% trypsin (Invitrogen) was added to cover the cell 
monolayer and the flask was incubated for 1 minute at 37°C. 5-10ml GMEM/FCS 
medium was added to quench the trypsin. The cell suspension was collected in a clean 
30ml Sterling universal (Scientific Laboratory Supplies) and centrifuged in an 
Eppendorf 5702 centrifuge at 1300rpm for 2.5 minutes. Cells were split in a ratio 1:5. 
Routinely cells were passaged every 2 days. 
 
2.3.3 Freezing ESCs, iPSCs and ALSCs 
Cells in tissue culture flasks were trypsinised as described above and centrifuged 
at 1300rpm for 2.5 minutes. Cells were resuspended in 1ml of GMEM/FCS medium 
with 10% dimethyl sulphoxide (DMSO) per 25cm2 flask and transferred into a cryotube 
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(Nunc) at 0.5ml per vial. Cryotubes were placed for overnight at -80°C freezer and then 
transferred to a liquid nitrogen cell bank (Series 2300, Custom biogenic Systems). 
 
2.3.4 Thawing ESCs, iPSCs and ALSCs 
Frozen cryotubes were brought from liquid nitrogen storage and placed 
immediately into 37°C waterbath. Once the cells were thawed they were transferred 
into 5ml of warm GMEM/FCS culture medium. The cell suspension was then 
centrifuged at 1300rpm for 2.5 minutes. The cells were then resuspended in 10ml of 
GMEM/FCS medium supplemented with LIF (for ESCs and iPSCs) or Activin A (For 
ALSCs) and plated into a 25cm2 flask. The media were then refreshed about 10 hours 
later. 
 
2.3.5 Lipofectamine transfection of ESCs and ALSCs 
1×106 of mouse ESCs were plated onto each well of a 6-well plate (Fisher). 250µl 
of OptiMEM (Invitrogen) were mixed with 3µl of Lipofectamine 2000 (Invitrogen) and 
left for 5 minutes at room temperature. 4µg of plasmid DNA (pCAGGFPIP) in another 
250µl OptiMEM was then added and the mix left for 20 minutes at room temperature. 
The DNA/Lipofectamine mixture was then added to the cells and rocked gently. After 
61
4.5 hours, the mixture was changed to ESC culture medium. Twenty-four hours later 
puromycin (Sigma) was added to the plates at a concentration of 1μg/ml. Media with 
puromycin were refreshed every other day. When appropriate (about 5 days), 
puromycin-resistant colonies were picked into 24-well plates (Fisher) and expanded.  
 
2.3.6 Embryoid body differentiation 
5×106 mouse ESCs or iPSCs were plated onto 9cm diameter bacterial grade Petri 
dishes (Scientific Laboratories Supplies) in GMEM/FCS or N2B27 medium to allow 
the formation of EBs for 14 days. Media were changed every 2 days. 
  
2.3.7 Derivation and passage of EpiSCs from ESCs or iPSCs 
Mouse ESCs or iPSCs were plated at a density of 1-2×104 per cm2 in fibronectin 
(1μg/ml, Millipore) coated plates. The media were changed to N2B27 containing 
12ng/ml Activin A and 8ng/ml FGF2 (Peprotech) 24 hours later. For passaging, cells 
were dissociated in 200u/ml collagenase IV (Gibco) at 37°C for 10 minutes. Then 
media were replaced with 1ml N2B27 and cells were mechanically scrapped by the 
tip of 5ml pipette (Starstedt). Cell suspension was collected in a clean 30ml Sterling 
universal with 5ml N2B27 and centrifuged at 1300rpm for 2.5 minutes. Cells were split 
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in a ratio 1:3 and passaged every 2-3 days. 
 
2.4 Histochemistry 
 
2.4.1 Immunocytochemistry of cultured cells 
Cells cultured on coverslips (VWR) were washed with PBS and fixed with 4% 
PFA for 10 minutes at room temperatures. After washing in PBST, cells were blocked 
with 3% donkey serum in PBST at room temperature for 20 minutes, and then 
incubated in primary antibody appropriately diluted with 3% donkey serum in PBST 
for overnight at 4ºC. After washing in PBST, cells were incubated with the 
fluorescence-conjugated secondary antibody appropriately diluted with 3% donkey 
serum in PBST in the dark for 2 hours at room temperature. The cells were then 
counterstained with DAPI. After washing in PBS, cells were mounted in mounting 
solution (DAKO) on microscopic slides (VMR).  
 
2.4.2 List of primary antibody 
Antigen Host Supplier Concentration 
Oct4 Rabbit Abcam 1:500 
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Otx2 Rabbit Millipore 1:500 
Sox2 Mouse Millipore 1:500 
SSEA1 Mouse Developmental Studies Hybridoma Bank 1:100 
 
2.4.3 List of secondary antibody 
Fluorophobe Antigen Host Supplier Concentration 
Alexa 488 Mouse IgG Donkey Invitrogen 1:200 
Alexa 488 Rabbit IgG Donkey Invitrogen 1:200 
Alexa 594 Mouse IgG Donkey Invitrogen 1:200 
Alexa 594 Rabbit IgG Donkey Invitrogen 1:200 
 
2.4.4 Imaging acquisition 
Bright field images were taken using Olympus IX51 inverted microscope. 
Fluorescent images were captured by a Leica TCS SP5 confocal microscope equipped 
with 405 Diode, Argon, DPSS 561, HeNe 594 and HeNe 633 lasers. Contrast and 
brightness of acquired images were carried out with Adobe Photoshop CS2 to enhance 
weak fluorescence and improve contrast.  
 
2.4.5 Alkaline phosphatase assay 
Cells expressing AP were detected by AP detection kit (Millipore) according to the 
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manufacturer’s instruction. Cells cultured in 6-well plate were fixed in 4% PFA for 2 
minutes. The fixative was removed and the cells were washed in 3ml PBS. 500ml 
Naphthanol/Fast Red Violet solution (Fast Red Violet:Naphthanol:water=2:1:1 v/v) 
was added and incubated in the dark for 15 minutes at room temperature. Then the 
staining solution was removed and the cells were washed in PBS for 5 minutes at room 
temperature. To determine the number of AP+ colonies, positively stained colonies 
were counted manually. Each set of values was expressed as means ± standard 
deviation.  
 
 
2.4.6 Karyotyping of number of chromosome 
Cells in a confluent T25 flask were treated with 1µg/ml colchicine (Sigma) for 2.5 
hrs at 37°C and then dissociated with 0.025% trypsin. The cell suspension was 
centrifuged at 1300rpm for 3 minutes. After washed in PBS, cells were resuspended in 
3ml PBS and 7ml 0.0375 M KCl hypotonic solution for 20 min at 37°C, and then 
centrifuged at 1300rpm for 3 minutes. 5ml 0.00375M KCl solution was added to 
resuspend pellet. After another centrifugation at 1300rpm for 3 minutes, the pellet was 
gently resuspended in 5ml methanol/acetic acid (3:1, v/v) for 30 minutes at room 
temperature. The cell suspension was centrifuged at 1300rpm for 3 minutes. The pellet 
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was resuspended in 200µl methanol/acetic acid. 2-3 drops of cell suspension were 
dropped to a microscopic slide. The slides were air-dried and mounted with 
Vectershield with DAPI (Vector Laboratories). The chromosome spread was 
photographed under Leica DMRB epifluorescence microscope.  
 
2.5 Microarrays 
To prepare desired DNA for microarray, RNeasy kit (Quiagen) was used according 
to the manufacturer’s instruction. 1×106 Cells were lysed and homogenized in 350µl 
buffer RLT and 3.5µl 14.3M 2-mercaptoethanol. RNA samples were used for 
hybridization on the Mouse Expression-Array-430.2.0 Genechips (Affymetrix) by 
David Chambers in Microarray Core Facility at the Kings College London. Three 
independent experiments in each cell line were analyzed. Data were loaded onto the 
DNA-Chip Analyzer (dChip; http://www.dchip.org) program for normalization, 
quantification and hierarchy clustering, or Genespring GX (Agilent) for screening and 
matching candidate gene markers. 
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2.6 Flow cytometry and sorting 
Cells were trypsinised and resuspended in PBS with 10% FCS at 4ºC and 
subjected to flow cytometry sorting to establish green fluorescent protein (GFP) 
positive cell line. Cell suspensions in PBS with 10% FCS, 0.5u/ml penicillin 
(Invitrogen) and 0.5µg/ml streptomycin (Invitrogen) were kept on ice and the cells 
were sorted directly into tubes containing ESC medium. Approximately 1×106 cells 
were sorted per sample using FACSaria flow cytometry (Becton Dickison Biosciences) 
and FACSaria software (Becton Dickison Biosciences). The sorting was performed by 
Phil Huxley in Flow Cytometry of MRC Clinical Sciences Centre. 
 
2.7 Embryology 
 
2.7.1 Maintenance of animals 
Mice were housed and bred in the Central Biomedical Science (CBS) of Imperial 
College London, according to the Animals (Scientific Procedures) Act (UK) 1986. 
Mice were kept in a 12 hours light, 12 hours dark cycle with the midpoint of the dark 
cycle at 1am. Mice aged 6 weeks or older were used for mating. For collection of 
embryos, matings were arranged and female mice were checked daily before 10am for 
67
the presence of a vaginal plug. 1pm on that day was designated as embryonic day (E) 
0.5 if presence of vaginal plug. Litters were with their mother until 3 weeks of age when 
they weaned. At weaning the mice were sexed. Scheduled mating was performed by the 
staff of Charles River. Maintenance of the mice, and breeding set-up were performed by 
the CBS staff. 
 
2.7.2 Blastocyst injection 
Blastocyst injection was performed as a service by Elodie Ndjetehe in Transgenic 
and Embryonic Stem Cell Laboratory of MRC Clinical Sciences Centre. 
 
2.7.2.1 Preparation of ESCs for injection 
Mouse ESCs were replated one day before injection in order to keep the cells in 
log phase. On the day of injection, a 25cm2 flask of mouse ESCs was dissociated by 
0.025% trypsin for 1 minute at 37°C. 5-10ml of ESC culture media was added to 
quench the trypsin. The cell suspension was collected in a clean 30ml Sterling universal 
and centrifuged at 1300rpm for 2.5 minutes. The supernatant was removed and 3ml of 
ESC culture media was added to resuspend the pellet. The tube was put on ice until the 
time of injection.  
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2.7.3 Morula aggregation 
 
2.7.3.1 Preparation of aggregation plate  
KSOM (Millipore) microdrops (roughly 3 mm in diameter) were made in a 3cm 
diameter tissue culture dish (Falcon) and covered with mineral oil (Sigma). Six 
depressions were made in each microdrop by pressing a sterilized darning needle 
(Milward) into the plastic by making slight circular movement.  
 
2.7.3.2 Preparation of morula-staged embryos  
The oviducts along with the upper part of the uterus attached were removed from 
2.5 d.p.c. CD1 pregnant females and placed into FHM medium (Millipore). After 
removing the adipose and vascular tissue, a blunted 30 gauge needle attached to a 1ml 
syringe filled with FHM was inserted into the infundibulum to flush out morula from 
the oviduct. The morula were collected using a mouth pipette and washed through a 
drop of FHM medium to remove any debris. To dissolve zona pellucida, groups of 6 
embryos were transferred to a drop of Acid Tyrode's (Millipore). As soon as the zona 
pellucid was completely dissoluted the embryos were washed in FHM drops. The 
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zona-free embryos were transferred to aggregation plates. One embryo was placed 
inside each depression.  
 
2.7.3.3 Aggregation with ESCs and ALSCs and morula-staged embryo 
On the day of aggregation, a 25cm2 flask of mouse ESCs or ALSCs were 
trypsinised and replated on a 10cm diameter bacterial grade culture dish and cultured in 
a 37ºC incubator for 2 hours to allow aggregation formation. Each cell aggregate (8-15 
cells) was placed in a depression in the microdrop containing a zona-free embryo, and 
cultured in a 37ºC incubator. After around 24 hours the blastocysts formed from 
aggregates. 
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Chapter 3 Establishment and Characterization of 
LIF-STAT3/Activin-Smad2 Dual Responsive Stem Cell Lines 
 
3.1 Introduction 
Several lines of evidence suggest that ESCs exist in metastable pluripotent states 
that fluctuate between ICM-like cells and lineage primed postimplantation epiblast 
(Bao et al., 2009; Chou et al., 2008; Hayashi et al., 2008; Lake et al., 2000; Rathjen et 
al., 1999). The presence of multiple pluripotent states were reflected by differential 
growth factor responsiveness (Chou et al., 2008; Lake et al., 2000; Rathjen et al., 1999), 
gene expression profile (Bao et al., 2009; Chou et al., 2008; Hayashi et al., 2008) and 
associated chromatin signatures (Hayashi et al., 2008). For example, Stella+ ESCs 
express ICM markers Rex1 and Pecam1. Furthermore, association of H3K4Me3 was 
found to be highly enriched in the promoter region of Stella, suggesting their ICM-like 
state. By contrast, Stella- ESCs express postimplantation epiblast marker Fgf5, and 
display a low enrichment of H3K4Me3 at Stella locus. Similarity, the gene expression 
profile of Rex1+ ESCs is more akin to the ICM, while Rex1- ESCs gene expression is 
closer to that of postimplantation epiblast. Furthermore, purified Rex1 or Stella positive 
and negative subpopulation can reestablish the heterogeneous expression of the starting 
ESC population within a few days of culture. This convertibility suggests that either a 
72
dynamic continuum or a binary alternation exists between ICM and postimplantation 
epiblast-like state.  
Attempts have been made to derive stable cell lines of an intermediate state (Chou 
et al., 2008; Rathjen et al., 1999). FAB-SCs are cells derived from the ICM using media 
containing BIO, Activin and FGF2 and feeder cells (Chou et al., 2008). These cells 
exhibit a gene expression profile as if they are a mixture of ESCs and EpiSCs. A brief 
stimulation with LIF induces their potential of teratoma formation and, at very low 
frequency, chimera formation. However, the FAB-SC cultures are not clonally derived. 
There is a possibility of contamination with ESCs which can be expanded in LIF. 
Another type of pluripotent cells, EPLCs, was generated from ESC population under 
MEDII condition (Lake et al., 2000; Rathjen et al., 1999). Compared to ESCs, these 
cells expressed relatively lower level of ICM marker Rex1 and higher level of epiblast 
marker Fgf5 (Lake et al., 2000; Rathjen et al., 1999). The EPLCs are unable to generate 
chimeric mice unless being reverted to LIF containing culture conditions (Rathjen et al., 
1999). Again, these studies were carried out at population level hence raised the 
question whether the apparent reversion was due to residual undifferentiated ESCs in 
MEDII condition. Here I describe the clonal generation of Activin and LIF-responsive 
cell lines displaying molecular and functional characteristics of an intermediate 
pluripotent state.  
73
 
3.2 Derivation of Activin and LIF-responsive stem cell (ALSC) lines from ESCs 
The self-renewal of EpiSCs depends on Activin/Smad2/3 signalling. Spontaneous 
reversion of EpiSC to ESC-like cultures on feeders in serum-containing media suggests 
that serum- or feeder-derived factors may facilitate the transition of a stem cell from 
EpiSCs to ESCs (Bao et al., 2009; Greber et al., 2010). Thus I hypothesized that cells 
with a differentiation status intermediate of ESCs and EpiSCs would respond to Activin 
in serum-containing media. I firstly cultured a feeder-free mouse ESC cell line 
E14Tg2a (Magin et al., 1992) in GMEM/FCS medium with addition of Activin 
(Activin condition). In the 10000 cells seeded in five 10 cm diameter gelatine-coated 
culture dishes, a total of 144 colonies were formed, picked and expanded independently 
in Activin. Thirty-four of the original clones were able to expand as undifferentiated 
morphology in Activin in 10 days (Figure 3.1). The rest of 110 clones became 
differentiated and were abandoned. Because their parental ESC population was 
dependent on LIF/STAT3 signalling, I then asked whether these undifferentiated cell 
lines were still responsive to LIF. To do this, I plated 1000 cells from each of the 34 
clones in GMEM/FCS medium either in the presence of LIF (LIF condition), Activin or 
no added factor for 5 days. AP staining was used to identify the undifferentiated 
colonies (Figure 3.1, 3.2). This experiment separated the 34 clones into three types. 
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Type 1, which contained 9 clones, generated numerous AP+ colonies under LIF whilst 
few AP+ colonies were seen in Activin or media alone. Type 2 group contains 12 cell 
lines. Cells of this group efficiently generated AP+ colonies in all culture conditions. 
The rest 13 cell lines belong to type 3. Cells from these clones generated very few AP+ 
colonies in media alone but formed numerous AP+ colonies in either LIF or Activin, 
thus displaying dual-responsiveness to LIF and Activin. These results demonstrate that 
a proportion of ESCs (0.13%) can, or can be induced to, respond to Activin whilst 
remain responsiveness to LIF for self-renewal.  Two of these dual-responsive cell lines, 
which I designated as ALSC1 and ALSC2, for Activin and LIF-responsive Stem Cells, 
were chosen for further investigation.  
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Figure 3.1 Generation of ALSCs from ESCs 
Schemematic showing the strategy used for generating ALSCs. 34 clones were 
established from 144 original colonies. Colony forming assay was performed for each 
of the 34 clones in LIF, Activin and media alone. 9 clones produced abundant AP+ 
colonies in LIF but few in Activin condition or media alone. 12 clones produced AP+ 
colonies in media alone while 13 clones generated abundant AP+ colonies in either LIF 
or Activin condition at similar efficiency with few AP+ colonies in media alone.  
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Figure 3.2 Colony forming assay of ALSC clones in LIF and Activin   
One thousand cells of each of the 34 clones were plated in LIF, Activin or media alone 
for 5 days followed by AP staining. The clones displaying similar responsiveness were 
grouped together. Clone 10 and 16 dually responsive to LIF and Activin conditions 
were designated as ALSC1 and ALSC2. 
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3.3 Basic characterization of ALSCs 
Similar to ESCs, ALSC1 and ALSC2 grew as round, compact colonies with 
dome-like appearance in response to Activin (Figure 3.3A). Most of the cells in ALSC1 
and ALSC2 displayed normal number of chromosomes (Appendix 1). These colonies 
were strongly positive to AP staining (Figure 3.3B). The immunocytochemical analysis 
of these cells revealed features similar to ESCs. Oct4 and Sox2 were homogenously 
expressed in the nucleus, while immunostaining of a surface antigen staged-specific 
embryonic antigen (SSEA1, Figure 3.3C-E) exhibited a ring pattern surrounding the 
nucleus. ALSCs did not express Otx2 (Figure 3.3F), which is upregulated in EpiSCs 
(Tesar et al., 2007). ALSCs underwent rapid differentiation under culture condition for 
FAB-SC cells containing FGF2, Activin and BIO (FAB medium) (Chou et al., 2008). 
Few morphologically undifferentiated ALSCs were present after 5 passages in FAB 
medium on MEF feeders, suggesting that the ALSCs are different from the FAB-SCs 
(Figure 3.3G).  
When cultured in media alone in bacterial grade petri dishes, ALSC1 and ALSC2 
formed EBs that displayed a similar size to those generated from ESCs (Figure 3.4A). 
The Oct4 and Nanog expression levels of EBs formed by ALSC1 and ALSC2 were 
quickly downregulated as those of ESCs. This observation suggests that ALSC1 and 
ALSC2 differentiate similarly to that of ESCs (Figure 3.4B-C). 
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Figure 3.3 Characterization of ALSCs. 
(A) The ALSC1 and ALSC2 grew as dome-like and compact colonies when propagated 
in Actinvin, which are positive to AP staining (B). (C-F) Antibody staining of ALSC1 
and ALSC2 for Oct4, Sox2, SSEA1 and Otx2. (G) Passage 5 ALSC1 and ALSC2 in 
FAB medium. Scale bar, 100μm. 
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Figure 3.4 Embryoid body differentiation of ALSCs. 
(A) The scheme of embryoid body (EB) differentiation in GMEM/FCS medium. 
ALSC1 and ALSC2 were plated in bacterial grade petri dishes and cells were 
collected and were analyzed by Q-PCR every other day. (B) EBs formed by ALSC1 
and ALSC2. (C-D) Decreased level of Oct4 and Nanog were observed as 
differentiation progress. Relative gene expression level was determined by normalizing 
to β-Actin. Scale bar, 100μm. 
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3.4 Early embryonic gene marker expression by ALSCs  
The gene expression pattern of pluripotent stem cells mirrors that of the 
embryonic cells from which these cells are derived. For example, ESCs express 
ICM-associated gene markers Pecam1, Rex1 and Stella (Furusawa et al., 2004; Payer et 
al., 2006; Rogers et al., 1991). On the other hand, EpiSCs show low levels of the above 
markers but high levels of Fgf5, Nodel, Otx2 and Foxa2 (Brons et al., 2007; Tesar et al., 
2007), which are expressed in postimplantation epiblast and early germ layers. 
Therefore, the expression patterns of these early embroynic genes could be used to 
evaluate their pluripotent state. 
To determine the cell state of ALSCs, their transcriptional expression of early 
embryonic gene markers were examined by Q-PCR. cDNA of ESCs and 
epiblast-derived EpiSCs (kindly provided by Sandra Pinho at Institute of Reproductive 
and Developmental Biology of Imperial College London) were used as respective 
controls (Ying et al., 2002). As expected, most ICM-associated gene markers, including 
Rex1, Stella, Klf4, Pecam1, and Nanog, were expressed at a low levels in EpiSCs as 
compared to ESCs (Figure 3.5A). EpiSCs also expressed lower levels of Sox2 than 
ESCs. However, a similar level of Oct4 was detected in ESCs and EpiSCs. 
Interestingly, ALSC1 expressed intermediate levels of Rex1, Klf4, Pecam1 and 
Nanog as compared to ESCs and EpiSCs while the level of Stella in ALSC1 was as low 
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as that in EpiSCs. Similarly, ALSC2 also expressed Rex, Klf4, Nanog and Stella at a 
level between ESCs and EpiSCs, although ALSC2 expressed a similar level of Pecam1 
to that in ESCs.  
By contrast, the early lineage markers, such as Brachyury, Nodal, Pitx2, Otx2, 
Gata6, Foxa2 and Fgf5, were expressed at a higher level in EpiSCs than in ESCs 
(Figure 3.4B). Again, the transcript levels of these genes in ALSC1 and ALSC2 were 
detected at an intermediate level between those in ESCs and EpiSCs. Taken together, 
these data demonstrate that the two ALSC lines have gene expression pattern distinct 
from ESCs and EpiSCs. This pattern indicates that ALSCs exist in an intermediate cell 
state between ESCs and EpiSCs. 
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Figure 3.5 Expression of early embryonic gene markers by ALSCs 
The expression profile of early embryonic gene markers in ESCs, ALSC1, ALSC2 and 
embryo-derived EpiSCs were analyzed by Q-PCR. (A) Rex1, Stella, Klf4 and Nanog 
expression levels were evidently decreased in both ALSC1 and ALSC2 compared to 
ESCs, whilst Oct4 levels were similar in ALSC1, ALSC2, ESCs and EpiSCs. (B) The 
expression of Fgf5, Brachyury, Pitx2, Otx2, Gata6, and Foxa2 in ALSC1 and ALSC2 
were detected at an intermediate level between ESCs and EpiSCs. Gene expression was 
normalized to β-Actin and shown as relative level to ESCs. 
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3.5 Histone modification at early embryonic genes of ALSCs and ESCs 
The expression pattern of early embryonic gene markers in ALSCs indicates 
their intermediate state, which could be reflected in their epigenetic status. I therefore 
performed chromatin immunoprecipitation (ChIP) to determine the histone 
modifications indicative of gene activation (H3K4Me3) and repression (H3K27Me3) 
in the genomic sequences surrounding the start codon and the coding region of a 
series of early embryonic gene markers including Oct4, Nanog, Pecam1, Rex1, Stella,  
Klf4, Otx2, and Fgf5. A bivalent gene Nkx2.2 (Bernstein et al., 2006) and another gene 
Myf5, which is known to be associated with H3K27Me3 in ESCs (Azuara et al., 2006), 
were used as controls. 
ChIP is a procedure used to detect the specific binding of a given protein to a 
genomic sequence. ChIP technique is based on the principle that formaldehyde form a 
covalent crosslink between the primary amines located on the specific protein to the 
adjacent DNA molecules (Weinmann et al., 2001). Following crosslinking, the cells are 
lysed and the cell extracts are sonicated to break the DNA into a smear fragment. The 
protein-DNA complex is immunoprecipitated by specific antibody against desired 
protein. The crosslink between protein and DNA are reversed by heating. The DNA 
fragment associated with the complex is then purified and identified by Q-PCR using 
primers targeting the suspected bound DNA sequence. ChIP thus provides indication of 
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protein-DNA interactions at given loci. In conjunction with high-throughput 
sequencing this technique can be applied to screen for transcription factor binding sites 
on a genome-wide scale (Bernstein et al., 2004).   
Consistent with previous findings, I found association of Nkx2.2 with both active 
H3K4Me3 and repressive H3K27Me3 in all cultures while Myf5 showed a preferential 
binding with H3K27Me3 (Figure 3.6). In keeping with their expression of Oct4 and 
Nanog, I observed high binding enrichments of H3K4Me3 at the Oct4 and Nanog locus 
in ESCs, ALSC1 and ALSC2 (Figure 3.6A). Binding of H3K4Me3 to Pecam1, Rex1, 
Stella and Klf4 were more apparent in ESCs than in ALSC1 and ALSC2. Otx2 and Fgf5 
revealed more pronounced H3K4Me3 binding in both ALSC lines than in ESCs. 
Complementary to the results of H3K4Me3, low association of H3K27Me3 were seen 
in Oct4 and Nanog in all cell lines (Figure 3.6B). Pecam1, Rex1, Stella and Klf4 
displayed more binding of H3K27Me3 in both ALSC lines than in ESCs. Binding of 
H3K27Me3 to Otx2 and Fgf5 were preferentially found in ESCs. These data are 
generally matched to the differential gene expression by ALSCs and ESCs 
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Figure 3.6 Histone modification at selected early embryonic genes of ALSCs 
ChIP analysis on histone modifications indicative of gene activation (H3K4Me3) and 
repression (H3K27Me3) in the promoters (-P) and the coding (-C) regions were 
examined for Oct4, Nanog, Pcam1, Rex1, Stella, Klf4, Otx2, Fgf5, Nkx2.2 and Myf5.  
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3.6 ALSCs are developmentally upstream of EpiSCs 
It has been shown that ESCs cultured in Activin and FGF2 in defined condition 
can turn into stable lines of EpiSCs (Guo et al., 2009). The gene expression and 
epigenetic profiling shown above suggests that ALSC1 and ALSC2 are 
developmentally upstream of EpiSCs. If this is the case, culturing ALSCs in Activin 
and FGF2 would turn these cells into EpiSCs. Indeed, ALSCs passaged in N2B27 
supplemented with Activin and FGF2 generated flat and compact EpiSC-like colonies 
(Figure 3.7A). After 5 or more passages the EpiSC-like cells became the predominant 
population (>90%). These cells were designed as Epi-ALSCs.  
Epi-ALSC1 and Epi-ALSC2 shared similar morphological feature with 
epiblast-derived EpiSCs. They were flat and compact compared to the dome-shaped 
colonies formed by ALSCs and ESCs (Figure 3.7A). Apart from Oct4, Sox2 and 
SSEA1, a proportion (30-40%) of Epi-ALSC1 and Epi-ALSC2 became Otx2+, a 
marker not expressed in ALSC (Figure 3.7B-E). Furthermore, Epi-ALSC1 and 
Epi-ALSC2 displayed early embryonic gene expression profile similar to EpiSCs rather 
than ESCs. This was exemplified by the maintenance of Oct4 and reduced level of Sox2, 
Nanog, Pecam1, Klf4, Stella and Rex1 (Figure 3.8A). Nodal, Pitx2, Brachyury, Gata6, 
Otx2, Foxa2 and Fgf5 expression by Epi-ALSC1 and Epi-ALSC2 were at similar levels 
to those by EpiSCs (Figure 3.8B). These findings provide further support that ALSCs 
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are distinct from EpiSCs and are developmentally upstream of EpiSCs.  
 
 
 
 
 
88
 
Figure 3.7 Characterization of EpiSCs derived from ALSCs. 
(A) Morphology of Epi-ALSC1 and Epi-ALSC2 cultured in N2B27 medium 
containing Activin and FGF2. (B-E) Antibody staining for Oct4, Sox2, SSEA1 and 
Otx2. Scale bar, 100μm.
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Figure 3.8 Q-PCR analysis for early embryonic gene markers of Epi-ALSCs. 
Q-PCR analysis of early embryonic gene markers in ESCs, Epi-ALSC1, Epi-ALSC2 
and embryo-derived EpiSCs. (A) Expression levels of Nanog, Pecam1, Klf4, Stella and 
Rex1 by Epi-ALSC1, Epi-ALSC2 and EpiSCs were lower than those by ESCs. (B) 
Nodal, Pitx2, Brachyury, Gata6, Otx2, Foxa2 and Fgf5 were highly expressed by 
Epi-ALSC1, Epi-ALSC2 and EpiSCs. Gene expression was normalized to β-Actin and 
shown as relative level to ESCs. 
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3.7 The signalling pathway usage by ALSCs 
Signalling pathways have been shown to play distinct roles in different pluripotent 
stem cells. For example, Activin/Smad2/3 pathway maintains the self-renewal of 
EpiSCs, but not ESCs, by directly regulates Nanog (Greber et al., 2010; Tesar et al., 
2007) .Therefore, I sought to investigate this signalling pathway usage by ALSCs. 
1×104 cells of ESCs, ALSC1, ALSC2, Epi-ALSC1 or Epi-ALSC2 were starved in 
N2B27 medium for 12 hours. The cells were then exposed to growth factors or 
chemical inhibitors for different time periods followed by analysis by Western blot or 
Q-PCR (Figure 3.9A). Medium alone was used as a control for each time point after 
starvation. Firstly I tested whether Nanog expression is coupled to Activin/Smad2/3 
signalling in ALSCs. Following a 24 hour treatment with Activin, I observed an 
increase of phosphorylated Smad2 (p-Smad2) in all cell lines tested (Figure 3.9B). 
This was coupled to an increased Nanog protein level in ALSC1, ALSC2 and 
Epi-ALSC1, but not in ESCs. In contrast, the addition of Activin inhibitor SB431542 
(SB) to ALSC1 and ALSC2 results in approximately 70% reduction of Nanog 
expression level, whereas the subsequent 4 hour Activin treatment in SB-treated 
ALSC1 and ALSC2 rescued the Nanog expression (Figure 3.9C). This response 
mirrors very closely to that of Epi-ALSC1 and Epi-ALSC2. Conversely, Nanog 
expression was not affected by the SB treatment in ESCs, suggesting that ALSCs and 
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EpiSCs shared similar response to Activin/Smad2/3 signalling.  
ERK signalling is another important pathway that plays a divergent role in 
different pluripotent state. The activation of ERK signalling promotes lineage 
commitment in mouse ESCs (Kunath et al., 2007; Stavridis et al., 2007), whereas it 
promotes the self-renewal of EpiSCs (Greber et al., 2010). I therefore tested the 
response of ALSCs to ERK signalling inhibition. Following a 24 hour treatment with 
ERK inhibitor PD0325901 in the growth factor starved cells, a clear induction of 
neuroectodermal markers Sox1 and Pax6 was observed in Epi-ALSC1 and 
Epi-ALSC2 (Figure 3.10). In contrast, ALSC1, ALSC2 and ESCs displayed 
significant upregulation of pluripotent marker Klf4. Thus the blockage of ERK 
signalling promotes differentiation in EpiSCs but could sustain self-renewal in ALSCs 
and ESCs.  
It has been shown that LIF/STAT3 signalling are involved in the maintenance of 
ESC self-renewal and regulate the expression of Socs3, Klf4 and Errb (Greber et al., 
2010; Niwa et al., 2009; Ying et al., 2003a), while EpiSCs are LIF-independent 
(Brons et al., 2007; Greber et al., 2010; Tesar et al., 2007). To ask whether 
LIF/STAT3 signalling is active in ALSCs, I exposed the growth factor starved cells to 
LIF for 4 hours and observed a clear induction of Socs3, Errb and Klf4 in ESCs, 
ALSC1 and ALSC2 (Figure 3.11A) In contrast, a 12 hour treatment with JAK 
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inhibitor JAKI resulted in more than 50% reductions of these gene markers in ESCs, 
ALSC1 and ALSC2 (Figure 3.11B). These reductions were recovered following a 4 
hour LIF treatment. On the other hand, the expressions of Socs3, Errb and Klf4 in 
Epi-ALSC1 and Epi-ALSC2 were unaffected by the treatment of LIF or JAKI. This 
observation supports the dependence of LIF in ESCs and ALSCs, while EpiSCs is not 
reliant on LIF.  
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Figure 3.9 Activin signalling is coupled to pluripotency in ALSCs 
(A) Cells were starved in N2B27 medium without addition of growth factors or 
chemical inhibitors for 12 hours and then treated as indicated. Cultures were then 
processed for Western Blot or Q-PCR. (B)The phosphorylation of Smad2 (p-Smad2) 
accompanied with an increase of Nanog expression in ALSC1, ALSC2 and 
Epi-ALSC1. (C) Addition of Activin inhibitor SB431542 (SB) to ALSC1 and ALSC2 
results in approximately 70% reduction of Nanog expression level, whereas 
subsequent 4 hour Activin treatment in SB-treated ALSC1 and ALSC2 rescued 
Nanog expression. In contrast, the expression level of Nanog in ESCs was unchanged 
after treatment of either SB or Activin. Gene expression was normalized to β-Actin 
and shown as relative level to no treatment at each time point. 
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Figure 3.10 Blockage of ERK promotes pluripotency of ALSCs 
In ESCs, ALSC1 and ALSC2, the expression levels of Sox1 and Pax6 remained 
identical and a clear induction of Klf4 occurred after treatment of ERK inhibitor 
PD0325901 (PD). By contrast, PD treatment upregulated Sox1 and Pax6 but did not 
affect the expression of Klf4 in Epi-ALSC1 and Epi-ALSC2. Gene expression was 
normalized to β-Actin and shown as relative level to no treatment at each time point. 
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Figure 3.11 Activation of LIF promotes pluripotency of ALSCs 
(A) Following 4 hour LIF treatment, clear inductions of Socs3, Errb and Klf4 were 
observed in ESCs, ALSC1 and ALSC2, while no gene expression alterations were 
noted in Epi-ALSC1 and Epi-ALSC2. (B) A 12 hour treatment with JAK inhibitor 
(JAKI) reduced the levels of Socs3, Errb and Klf4 in ESCs, ALSC1 and ALSC2, 
whereas a subsequent 4 hour LIF treatment in JAKI-treated ESCs, ALSC1 and 
ALSC2 rescue their gene expressions. By contrast, the expression of Socs3, Errb and 
Klf4 was not altered after treating Epi-ALSC1 and Epi-ALSC2 with either JAKI or 
LIF. Gene expression was normalized to β-Actin and shown as relative level to no 
treatment at each time point. 
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3.8 ALSCs generate chimeras 
ESCs readily colonize chimeras while cells with a state close to epiblast, such as 
EpiSCs, FAB-SCs and EPLCs, do not integrate into the ICM (Chou et al., 2008; 
Rathjen et al., 1999; Tesar et al., 2007). This observation raises the question whether the 
intermediate state of ALSCs impedes their capability of ICM contribution and the 
generation of chimera.   
 
3.8.1 Morula aggregation 
I firstly tested the ability of ALSCs in contributing blastocyst formation by morula 
aggregation. Morula aggregation involves culturing morula stage embryos with cell 
aggregates in vitro to the blastocyst stage (Wang and Jaenisch, 2004). The major 
advantage of morula aggregation is that it does not need specialized equipment and 
technical skills, thus makes this transgenic technique accessible to a wide range of 
laboratories as a platform for testing pluripotency. Using GFP-labeled ESCs, the 
chimeric embryos can be identified quickly and easily by visualizing GFP expression in 
the chimeric blastocyst.  
ALSC1 and E14Tg2a ESCs constitutively expressing GFP were generated by 
introducing a GFP expression construct pCAGGFPIP (Appendix 2). After 10 days of 
puromycin selection, stable GFP expressing transfectants were sorted by FACS and 
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subsequently maintained in Activin condition. These cultures, designated as 
ALSC1-GFP and E14-GFP, respectively, contained more than 95% of GFP+ cells. For 
morula aggregation, a clump of 8-15 GFP-labeled cells were placed together with a 
morula-staged embryo. After culture for 24 hours, the morula embryos progressed to 
the blastocyst stage. Out of 56 blastocysts developed in the ALSC1-GFP aggregation 
group, 19 (33.93%) contained GFP+ cells (Figure 3.12), while 31 of 58 (53.45%) 
blastcysts in the E14-GFP control aggregation contained GFP+ cells. All GFP+ cells 
were observed in the ICM. This data demonstrate that the ALSC1 can contribute to 
blastocyst formation, as of ESCs.  
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Figure 3.12 Colonization of ALSCs into blastocysts. 
Morula embryos were aggregated with ALSC1-GFP and E14-GFP, and their 
colonization into the blastocysts was examined 24 hours later. (A) ALSC1-GFP 
displayed colonization efficiency slightly lower than E14-GFP. (B) GFP signals were 
detected in the ICM of blastocysts for both E14-GFP and ALSC1-GFP aggregations. 
Scale bars, 200μm. 
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3.8.2 Blastocyst injection 
Blastocyst injection was also used to determine chimera contribution by the 
ALSCs (Gardner, 1968; Gardner and Lyon, 1971).  This technique entails the 
introduction of 7-15 ESCs into the blastocyst cavity by microinjection. The donor ESCs 
are able to contribute to the ICM allowing the generation of chimeras. Compared to 
morula aggregation, blastocyst injection is able to generate chimera with higher 
efficiency (Peli et al., 1996). This may attribute to the fact that this procedure provides 
an opportunity to select ‘good’ ESCs by morphological criteria.  
After injection of ALSC-GFP into blastocyst cavity, embryos in a background of 
C57BL/6 were transferred into CBA/B6 pseudopregnant female mice. In the 8 
mid-gestation embryos taken from a 9.5 d.p.c. pseudopregnant mouse, 6 of them 
displayed high contribution of ALSC1-GFP (Figure 3.13A). However, these chimeric 
embryos were smaller than the non-chimeric embryos taken from the same host, and 
lack of the features of 9.5 d.p.c. embryos, such as turning of embryos, forelimb buds 
and subdivided forebrain vesicles (Theiler, 1972). None of the 38 live born pups were 
chimeric (Figure 3.13B). 
 Taken together, the above data demonstrates the capability of ALSC1 to integrate 
to ICM and form chimeric embryos. However, the intermediate state of ALSC1 may be 
incompatible with the developmental process and lead to the incapability of generating 
100
live born chimeric pups. 
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Figure 3.13 Generation of chimeric embryos from ALSCs. 
Blastocyst embryos were injected with ALSC1-GFP. (A) ALSC1-GFP form chimeric 
embryos taken from 9.5 d.p.c. pseudopregnant female. (B) No chimera was obtained in 
the 38 live pups. Scale bars, 400μm. 
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3.9 ALSCs differentiate faster than ESCs in vitro 
As shown in 3.4, ALSC1 and ALSC2 expressed lower level of Rex1 and Stella 
than ESCs. Rex1- and Stella- ESCs have been shown to display an accelerated temporal 
kinetics during in vitro differentiation (Hayashi et al., 2008; Toyooka et al., 2008). Thus 
I performed EB differentiation of ALSC1 and ALSC2 cells and examined the temporal 
expression of a panel of somatic gene markers 
 
3.9.1 Neuroectodermal differentiation of ALSCs 
To efficiently generate neuroectodermal lineages, I used the chemically defined, 
serum-free N2B27 culture medium for EB differentiation (Xia et al., 2007; Ying and 
Smith, 2003). This condition allows the generation of a high proportion of neural cells 
(Xia et al., 2007). To evaluate the temporal kinetics of neuroectodermal differentiation, 
EBs were collected every other day from day 0 to day 14 of differentiation and the 
expression levels of neural precursor (Pax6, Nestin) and neuronal markers (Tubb3) 
were assessed by Q-PCR (Figure 3.14A). Pax6 is expressed broadly in early vertebrate 
neuroepithelium and in ESC-derived neural progenitors (Bibel et al., 2004; Hill et al., 
1991). In ALSC1 and ALSC2 cultures, the level of Pax6 began to increase at day 6 of 
differentiation (Figure 3.14B). In contrast, upregulation of Pax6 in ESC cultures was 
not observed until day 8 of differentiation. Nestin is another gene expressed throughtout 
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the developing neuroepithelium (Lendahl et al., 1990). In ALSC1 and ALSC2, 
expression of Nestin began to increase after 8 days of differentiation, two days earlier 
than that in ESCs (Figure 3.14C). Tubb3 is an intermediate filament expressed by 
postmitotic neurons and neural progenitors in their last cell cycle (Liu et al., 2007a). On 
day 8 of differentiation, significant upregulation of Tubb3 can be detected in ALSC1 
and ALSC2 (Figure 3.14D). In ESCs, this upregulation was not seen until day 12 of 
differentiation. These data demonstrates an accelerated neuroectodermal differentiation 
in ALSCs compared to ESCs.  
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Figure 3.14 Neural differentiation of ALSCs 
(A) ALSC1, ALSC2 and ESCs were subjected to EB differentiation in N2B27. The 
expression levels of stage specific neural gene marker (B) Pax6, (C) Nestin and (D) 
Tubb3 was analyzed by Q-PCR. Relative gene expression level was normalized to 
β-Actin.  
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3.9.2 Mesodermal and endodermal differentiation from ALSCs 
When differentiated in serum-containing condition most of the cells in EBs are 
committed to non-neural fate (Doetschman et al., 1985). Therefore, it is possible to 
evaluate the temporal progression of mesodermal and endodermal differentiation using 
EB differentiation in GMEM/FCS medium. Again the EBs formed by ALSCs and 
ESCs were collected every other day during a total of 14 days of differentiation, and the 
expression levels of mesoderm (Brachyury, Goosecoid) and endoderm (Bmp4, Afp) 
genes were assessed by Q-PCR (Figure 3.4A). Brachyury is expressed in the late 
epiblast and early mesodermal structure (primitive streak) in the mouse embryo and is 
widely used as an early mesodermal marker for ESC differentiation (Herrmann, 1991). 
Brachyury transcript peaks at day 6 of ESC differentiation, 2 days later than that of the 
two ALSCs (Figure 3.15A). Goosecoid is expressed in the Spearman organizer during 
gastrulation and is also regarded as a mesodermal marker of in vitro differentiation 
(Belo et al., 1998). In ALSC1 and ALSC2, the level of Goosecoid began to increase at 
day 4 of differentiation (Figure 3.15B). In ESCs, upregulation of Goosecoid was 
observed at day 8 of differentiation. Bmp4 is expressed in a number of endodermal 
structures after gastrulation, and is frequently used to monitor the progression of in 
vitro differentiation (Grabel et al., 1998; Liu et al., 2007b; Perea-Gomez et al., 1999). In 
ALSC1 and ALSC2, the increase of Bmp4 occurred at day 4 of differentiation, 2 days 
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earlier than that in ESCs (Figure 3.15C). Afp is expressed in fetal liver and its 
expression is repressed after birth (Kamiya et al., 1999). The expression of Afp is used 
to observe the progression of in vitro endodermal differentiation (Abe et al., 1996). In 
ALSC1 and ALSC2, the expression of Afp began to increase at day 8 of differentiation 
(Figure 3.15D). In ESCs, the level of Afp was not increased until day 12. These 
observations suggest that mesodermal and endodermal differentiation in ALSCs were 
accelerated.  
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Figure 3.15 Mesodermal and endodermal differentiation in ALSCs 
ALSC1, ALSC2 and ESCs were subjected to EB differentiation in GMEM/FCS. The 
expression levels of mesodermal gene marker (A) Brachyury, (B) Goosecoid, and 
endodermal gene marker (C) Bmp4, (D) Afp were analyzed by Q-PCR. Relative gene 
expression level was normalized to β-Actin.  
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3.10 Summary 
In this chapter, I described the generation and characterization of clonogenic 
stable cell lines ALSCs that can be maintained by either Activin or LIF. The expression 
analysis, reinforced by matching histone modification at key pluripotent gene locus, 
provides strong support that ALSCs exist at a stage intermediate of the two pluripotent 
stem cell state. ALSCs share the response to Activin/Smad2/3 signalling with EpiSCs, 
while retain responsiveness to ERK inhibition and LIF/STAT3 signalling similar to 
ESCs. Furthermore, ALSCs are capable of integrating to the ICM and form chimeric 
embryos. The analysis of EB differentiation revealed accelerated temporal 
differentiation kinetics in all three germ-layers. This is the first study proving the 
existence of intermediate pluripotent state at single cell level. These data expand our 
knowledge about the regulation and transition between different pluripotent states.
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Chapter 4 Analysis of Activin/LIF Dual-Responsive iPSCs 
 
4.1 Introduction  
The generation of pluripotent cells from differentiated adult cells offers 
unprecedented promise for in vitro disease modeling, pharmaceutical screening, 
toxicology and regenerative medicine. However, the reprogramming process is 
inefficient and sometimes incomplete (Mikkelsen et al., 2008; Silva et al., 2008; Silva 
et al., 2006; Takahashi et al., 2007; Takahashi and Yamanaka, 2006). In the early report 
of iPSCs, only one out of 2,000 plated fibroblasts were reprogrammed to pluripotent 
cells (Takahashi et al., 2007). Several groups reported that the cells were often only 
partially reprogrammed and were unable to form germline-transmissible chimera 
(Mikkelsen et al., 2008; Silva et al., 2008; Silva et al., 2006; Takahashi and Yamanaka, 
2006). For example, complete pluripotent reprogramming was not achieved in the first 
iPSC lines generated by Yamanaka and colleagues in 2006 (Takahashi and Yamanaka, 
2006). These cells were converted from MEF and tail-tip fibroblasts of mice 
homozygous carrying a knockin neomycin-reporter cassette into the Fbx15 gene locus. 
These Fbx15-selected iPSCs exhibited morphology similar to ESCs, and were not 
senescent after prolonged passaging, distinct from MEFs and tail-tip fibroblasts. They 
displayed abilities in formation of EBs and teratoma. However, their gene expression 
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and histone modification patterns suggest that some clones exist in a different cell state 
from ICM-like ESCs. For example, in many colones the endogenous expressions of 
Oct4, Sox2 and Nanog remained low. It appeared that dimethylation of histone H3 
lysine 9 and acetylation of histone H3 in the Oct4 and Nanog promoter region varied in 
different clones. Despite their ability to give rise to chimeric embryos, no adult 
chimeras were obtained from these Fbx15-selected iPSCs. Partially reprogrammed cell 
lines exhibiting a cell state distinct from the ICM were also established by the Oct4- or 
Nanog-selection (Mikkelsen et al., 2008). Compare to fully reprogrammed iPSCs, 
these partial reprogrammed cells expressed low level of Rex1 and Stella, and have more 
pluripotency-specific gene promoters lacking H3K4Me3 (Mikkelsen et al., 2008). 
These finding suggest that transcription factor reprogramming can convert somatic 
cells to multiple cell states.  
It is possible that distinct pluripotent stem cell states can be stabilized by specific 
culture condition. For example, most of mouse ESCs cultured in chemically-defined 
culture condition in the presence of LIF and two small molecule inhibitors (2i), 
CHIR99021 and PD0325901 (2i-LIF), could be restrained in ICM-like state. Under 
this condition, WNT signalling is promoted by the GSK-3β inhibitor CHIR99021, 
while ERK pathway is suppressed by PD0325901 (Figure 1.2D-E) (Ying et al., 2008). 
Under another chemically-defined condition with addition of Activin and FGF2, mouse 
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ESCs can be moved forward to postimplantation epiblast-like state (Guo et al., 2009). 
In chapter 3, I described an intermediate pluripotent state of ALSCs that can be 
efficiently maintained in Activin and serum. In this chapter, I examined Activin 
responsiveness of four iPSC lines which were reprogrammed from mouse 
brain-derived neural stem cells (Silva et al., 2008) and MEF (Kaji et al., 2009), 
respectively. My data revealed that two of the iPSC clones showed comparable plating 
efficiency in Activin and LIF. The gene expression and histone modification patterns 
and differentiation kinetics demonstrated an intermediate cell state of these two iPSC 
lines. A brief exposure of these cells to 2i-LIF changes their cell state to ICM-like state. 
These studies clearly delineate the metastatic states of some iPSC lines.  
 
4.2 Activin responsiveness of four iPSC lines  
Data presented in chapter 3 demonstrated that an intermediate pluripotent state can 
be sustained by Activin in serum. To ask whether any iPSCs also stay in this 
intermediate cell state, I tested the responsiveness of four iPSC lines to Activin. Two 
cell lines, originally called 2i-iPS and to be referred to as iPSC1 and iPSC2, 
respectively, in this thesis, were obtained from Austin Smith’s laboratory at the 
Wellcome Trust Center of Stem Cell Research of University of Cambridge. Both cell 
lines were reprogrammed from mouse brain-derived neural stem cells of 129/MF1 
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hybrid background by retroviral vectors, and have a Oct4-GFP reporter linked to a 
puromycin selection cassette (Silva et al., 2008). iPSC1 was reprogrammed by Oct4 
and Klf4, while iPSC2 was reprogrammed by Oct4, Klf4 and c-Myc. Two other iPSC 
clones, imO2Ec3 and imO3c8, (here referred to as iPSC3 and iPSC4, respectively) 
were obtained from Dr. Keisuke Kaji at the Institute of Stem Cell Research, University 
of Edinburgh (Kaji et al., 2009). These iPSCs were reprogrammed from MEF of 129 
genetic background by plasmid vectors and had the reprogramming factors excised.  
Before being transferred to our laboratory, iPSC1 and iPSC2 were cultured in 
2i-LIF (Silva et al., 2008; Ying et al., 2008). At the time these cells were acquired, 2i 
were not commercially available. I therefore cultured these iPSC lines in GMEM/FCS 
medium with presence of LIF, the routine ESC culture condition in our laboratory. 
After an initial adaptation period when many cells died, most cells in my LIF condition 
exhibited undifferentiated morphology and expressed GFP. Most iPSC1 and iPSC2 
cells had normal number of chromosomes (Appendix 1). iPSC3 and iPSC4 were 
originally reprogrammed in serum-LIF condition and were cultured in the same 
condition in our laboratory. The chromosome numbers of iPSC3 and iPSC4 were 39 
and 40, respectively (data provided by Dr. Keisuke Kaji).  
To evaluate the responsiveness of iPSCs to different extrinsic factors, I cultured 
these iPSC lines and ESCs in GMEM/FCS medium with Activin, LIF or no exogenous 
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factors, respectively, as described in Chapter 3. 1×106 cells were seeded in one T25 
flask in different culture conditions and cultures were passaged every other day as of 
routine ESC propagation. During the first 5 passages, all cell lines in LIF condition 
retained undifferentiated morphological features, characterized by large nuclei with 
dark nucleoli and limited cytoplasm (Figure 4.1A-E). In contrast, the vast majority of 
the cells in no factor control condition differentiated quickly and the cultures became 
morphologically heterogeneous (Figure 4.1F-J). Under Activin condition, ESCs 
differentiated quickly and exhibited similar morphological and population changes to 
the cultures without LIF (Figure 4.K). However, both iPSC1 and iPSC2 maintained 
homogeneous undifferentiated morphology at passage 5 in Activin (Figure 4.1L-M). 
Following exposure to Activin, iPSC3 quickly differentiated with few undifferentiated 
cells left after 5 passages (Figure 4.1N). Although evident differentiation was also 
noticed in iPSC4 cultured in Activin, around 30% of cells maintained morphologically 
undifferentiated at passage 5 (Figure 4.1O). This result suggests that the self-renewal of 
iPSC1 and iPSC2 can be efficiently maintained by Activin, while iPSC4 is partially 
responsive to Activin.  
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Figure 4.1 Maintenance of iPSCs and ESCs in different culture condition 
(A-E) LIF maintains ESCs and iPSC1-4. (F-J) Cells of all 5 cell lines differentiated in 
media alone. (K-N) iPSC1 and iPSC2 remained undifferentiated in Activin, whereas 
ESCs and iPSC3 prominently differentiated in the same condition. (O) A proportion of 
iPSC4 retained undifferentiated in Activin. All cell lines were at passage in the given 
condition. Scale bar, 100μm. 
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 4.3 Activin and LIF dual-responsive iPSC lines  
The above experiment finding suggests that some iPSC lines are responsive to 
Activin. To investigate whether manipulation in Activin affects LIF responsiveness of 
these iPSC lines, ESCs and iPSCs originally cultured in LIF were split every other day 
in Activin. 1000 cells were seeded in a well of 6-well plate in LIF, Activin and no factor 
control every two passages and the undifferentiated colonies were determined using AP 
staining 5 days later (Figure 4.2A). All cell lines produced few AP+ colonies in media 
alone, irrespective of the number of passages in Activin. Propagation of ESCs in 
Activin resulted in a rapid reduction of clonal efficacy in LIF (from 338.33 ± 54.50 at 
passage 0 to 14.00 ± 5.29 at passage 4) (Figure 4.2B). This was accompanied by a small 
increase in the number of AP+ colonies in Activin (12.33 ± 1.53 at passage 0 and 36.00 
± 6.08 at passage 4, respectively). However, iPSC1 and iPSC2 generated 391.67 ± 
27.30 and 390.33 ± 80.01 AP+ colonies, respectively, in LIF even after 10 passages in 
Activin (Figure 4.2C-D). A similar number of AP+ colonies, 358 ± 16.09 for iPSC1 and 
403.33 ± 39.72 for iPSC2 were also produced by sister cells plated in Activin. After 4 
passages, iPSC3 only produced 31.33 ± 10.07 AP+ colonies in LIF condition (Figure 
4.2E). This represented a sharp decrease compared to the 239.00 ± 19.67 AP+ colonies 
formed by these cells in the same culture condition before being propagated in Activin 
at passage 0. A similar numbers of AP+ colonies were formed in Activin (38.67 ± 5.13) 
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or media alone (26.33 ± 5.13) in passage 4, suggesting that Activin cannot support the 
self-renewal of most cells in iPSC3. In LIF condition, iPSC4 formed 194.67 ± 38.80 
AP+ colonies at passage 0, while only 57.33 ± 8.39 AP+ colonies were generated after 4 
passages in Activin (Figure 4.2F). In Activin condition, these iPSCs produced 41.33 ± 
8.33 AP+ colonies at passage 0 and 90.00 ± 16.52 at passage 4. In contrast, only 27.00 ± 
7.00 AP+ colonies were generated in media alone condition by passage 4. Thus iPSC1 
and iPSC2 can respond to both LIF and Activin, while iPSC4 displayed partial 
responsiveness to Activin.   
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Figure 4.2 Responsiveness of iPSC1-4 to Activin  
(A) ESCs and iPSC1-4 were passaged in Activin condition.1000 cells from every two 
passage were replated in different culture condition. The undifferentiated colonies were 
identified by AP staining. (B) In ESC cultures, very few AP+ colonies formed in any 
conditions after 4 passages in Activin. (C-D) iPSC1 and iPSC2 formed roughly equal 
number of AP+ colonies in both LIF and Activin conditions in each passage. (E) iPSC3 
generated few AP+ colonies in any conditions after four passages in Activin. (F) iPSC4 
generated a reduced number of AP+ colonies in either LIF or Activin after 4 passages in 
Activin. Few AP+ colonies were produced in all no factor control culture. 
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4.4 Clonal analysis of dual-responsive iPSCs  
While the above experiment supported a dual responsiveness of LIF and Activin 
in iPSC1 and iPSC2, it remained possible that LIF and Activin responsive 
subpopulation were expanded. To demonstrate that dual responsiveness occurs at single 
cell level, clonal analysis was performed in iPSC1, iPSC2 and iPSC4. 500 cells of each 
cell line were seeded in LIF condition in a 10cm diameter culture dish, and 10 
undifferentiated colonies were randomly picked from each parental line after 10 days. 
The cells were independently expanded to stable subclones in LIF condition. The 
self-renewal capacity of these subclones in LIF and Activin conditions was then 
determined as described before (Figure 4.3A). As shown in Figure 4.3B-C, each 
subclone of iPSC1 and iPSC2 generated comparable numbers of AP+ colonies in either 
LIF or Activin condition. As observed previously, few AP+ colonies were found in 
media alone cultures. These results provide strong support that iPSC1 and iPSC2 dually 
respond to LIF and Activin at single cell level. On the other hand, out of 10 subclones 
derived from iPSC4, 5 of them gave rise to AP+ colonies only in the LIF condition 
(Figure 4.3D). 3 subclones generated AP+ colonies in either LIF or Activin. The rest of 
the 2 subclones appeared to be factor independent as AP+ colonies were produced in 
LIF, Activin or media alone. These data suggested that only a proportion of iPSC4 can 
respond to both LIF and Activin.   
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Figure 4.3 Clonal analysis of the dual responsiveness of LIF and Activin in iPSC1, 
iPSC2 and iPSC4 
(A) Ten colonies of iPSC1, iPSC2 and iPSC4 formed in LIF condition were picked and 
expanded as stable subclones. 1000 cells of each clone were plated in different culture 
conditions and stained for AP 5 days later. (B-C) All iPSC1 and iPSC2 subclones 
generated similar number of AP+ colonies in either LIF or Activin condition, but few 
AP+ colonies in media alone. (D) 5 subclones (clone 1, 2, 8, 9, 10) of iPSC4 generated 
numerous AP+ colonies only in LIF condition, 3 subclones (clone 3, 4, 5) formed 
comparable number of AP+ colonies in either LIF or Activin condition, and 2 subclones 
(clone 6, 7) produced AP+ colonies also in media alone.   
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4.5 BMP4 cannot replace serum to parternership with Activin  
The maintenance of ALSCs, iPSC1 and iPSC2 in Activin in FCS suggests that 
unknown factors in serum may contribute to the self-renewal of pluripotent stem cells. 
One of the components of serum, BMP4, has been used as a serum replacement while 
culturing ESCs in serum-free condition with LIF (Ying et al., 2003a). I therefore tested 
whether the combination of Activin and BMP4 in N2B27 medium can sustain the 
undifferentiated status of iPSC1 and iPSC2. However, both cell lines differentiated 
quickly and few undifferentiated cells left after 5 times of passage in this condition 
(Figure 4.4). This result indicates that BMP4 cannot be a substitute of serum to sustain 
the self-renewal of iPSC1 and iPSC2 in cooperation with Activin.  
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Figure 4.4 Maintenance of iPSC1 and iPSC2 in Activin and BMP4 
The majority of iPSC1 and iPSC2 differentiated following 5 passages in Activin and 
BMP4, Scale bar, 100μm. 
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4.6 Pluripotent marker expression by iPSC cultured in LIF and Activin  
Similar to ESCs, iPSC1 and iPSC2 in my LIF culture condition formed round, 
dome-shaped and AP+colonies (Figure 4.5A-B). Most of cells were positive to 
pluripotent markers Oct4, Sox2 and SSEA1 (Figure 4.5C-E). Unlike EpiSCs, cells of 
neither the two iPSC lines stained positive for Otx2 (Figure 4.5F). To ask whether 
iPSC1 and iPSC2 cultured in Activin condition (iPSC-A) retained similar 
morphological features, I passaged these cells to Activin condition (iPSC-A) for 10 
times and examined their morphological and gene transcriptional features. Similar 
round and dome-shaped AP+ colonies were generated by iPSC1-A and iPSC2-A 
(Figure 4.5A-B). Oct4, Sox2 and SSEA1 were expressed in majority of cells, while 
Otx2 was absent (Figure 4.10C-F). These data demonstrates iPSC1 and iPSC2 express 
pluripotent markers while cultured in either LIF or Activin.  
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Figure 4.5 Pluripotent marker expression by iPSC1 and iPSC2 cultured in LIF 
and Activin 
(A) In LIF, iPSC1, iPSC2 grew as dome-like and compact colonies, which are positive 
to AP staining (B). Similar morphological feature can be noted while cultured iPSC1 
and iPSC2 in Activin (iPSC1-A and iPSC2-A). (C-F) Antibody staining of iPSC1, 
iPSC2, iPSC1-A and iPSC2-A for Oct4, Sox2, SSEA1 and Otx2. Scale bar, 100μm.  
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4.7 Expression and histone modification of early embryonic gene markers by 
iPSCs  
The dual responsiveness of iPSC1 and iPSC2 suggested they may exist in an 
intermediate state like that of the ALSCs. Thus the early embryonic gene marker 
expression profile, as described in chapter 3, was determined by Q-PCR. Similar levels 
of Oct4 and Nanog were detected in ESCs, iPSC1 and iPSC2 (Figure 4.6A). Both iPSC 
lines expressed Rex1, Stella, Klf4, Sox2 and Pecam1 at a level intermediate between 
ESCs and EpiSCs. Similar to ALSCs, both iPSC lines expressed intermediate level of 
Pitx2, Brachyury, Otx2, Foxa2, and Fgf5 as compared to ESCs and EpiSCs (Figure 
4.6B). Very low levels of Gata6 and Nodal were observed in both iPSC lines and ESC. 
While cultured in Activin, iPSC1-A and iPSC2-A cells had reduced levels of Nanog, 
Pecam1, Klf4, Stella, and Rex1 compared to ESCs (Figure 4.6C). Similar to my 
observations with ALSCs, the expression levels of Nodal, Pitx2, Brachyury, Gata6, 
Otx2, Foxa2 and Fgf5 by iPSC1-A and iPSC2-A were intermediate between those by 
ESCs and EpiSCs (Figure 4.6D). These data demonstrate either LIF or Activin 
condition hold an intermediate state in iPSC1 and iPSC2.  
To validate the gene expression changes in iPSC1 and iPSC2, the enrichments of 
histone modification H3K4Me3 and H3K27Me3 in promoter and coding loci of a few 
early embryonic genes were examined by ChIP. In keeping with their active 
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transcription state, the promoter and coding loci of Oct4, Nanog and Pecam1 were 
highly enriched with H3K4Me3 (Figure 4.7A). ESC displayed higher enrichments of 
H3K4Me3 than iPSC1 and iPSC2 at Rex1, Stella and Klf4. Otx2 and Fgf5 revealed 
significantly higher enrichments of H3K4Me3 in both iPSC lines than those in ESCs. 
On the other hand, low enrichment of H3K27Me3 was seen in Oct4, Nanog and 
Pecam1 in all cell lines (Figure 4.7B). The association of H3K27Me3 with Rex1, Stella 
and Klf4 were higher in both iPSC lines than those in ESCs. In contrast, the association 
of H3K27Me3 with Otx2 and Fgf5 were reciprocally lower in both iPSC lines than 
those in ESCs. These data are consistent with the respective gene expression 
differences observed in iPSC1, iPSC2 and ESCs. However, while Pecam1 was 
expressed at a lower level in iPSCs than in ESCs, I observed no difference in H3K4Me3 
and H3K27Me3. Nevertheless, these data suggest that iPSC1 and iPSC2 exist at an 
intermediate state between ICM- and postimplantation epiblast-like states. 
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Figure 4.6 Expression of early embryonic gene markers by iPSC1 and iPSC2 
cultured in LIF and Activin 
The expression profile of early embryonic gene markers by ESCs, iPSC1, iPSC2, 
iPSC1-A, iPSC2-A and embryo-derived EpiSC were analyzed by Q-PCR. (A) 
Expression of Rex1, Stella, Klf4, Pecam1, Sox2 and Oct4 in iPSC1 and iPSC2. (B) 
Expression of Fgf5, Brachyury, Nodal, Pitx2, Otx2, Gata6, and Foxa2 in iPSC1 and 
iPSC2. (C) Expression of Rex1, Stella, Klf4, Pecam1, Sox2 and Oct4 in iPSC1-A and 
iPSC2-A. (D) Expression of Fgf5, Brachyury, Nodal, Pitx2, Otx2, Gata6, and Foxa2 in 
iPSC1-A and iPSC2-A. Gene expression was normalized to β-Actin and shown as 
relative level to ESCs. 
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Figure 4.7 Histone modification at selected early embryonic genes of iPSC1 and 
iPSC2 cultured in LIF 
ChIP analysis on histone modifications indicative of gene activation (H3K4Me3) and 
repression (H3K27Me3) in the promoters (-P) and the coding (-C) regions were 
examined for Oct4, Nanog, Pcam1, Rex1, Stella, Klf4, Otx2, Fgf5, Nkx2.2 and Myf5.  
129
4.8 iPSCs differentiated to EpiSCs in Activin and bFGF 
To confirm iPSC1 and iPSC2 were developmental upstream to EpiSCs, iPSC1 and 
iPSC2 were cultured in feeder-free EpiSC condition (ie. N2B27 medium in the 
presence of Activin and FGF2). They differentiated to EpiSCs (Epi-iPSCs) after around 
5 passages. Epi-iPSC1 and Epi-iPSC2 shared similar morphological feature with 
epiblast-derived EpiSCs. They were flat and compact compared to the dome-shaped 
and dense ESC colonies (Figure 4.8A). These colonies stained positive to Oct4, Sox2 
and SSEA1. And a proportion of cells (around 30-40%) in Epi-iPSC1 and Epi-iPSC2 
expressed epiblast marker Otx2 (Figure 4.8B-E). Epi-iPSC1s and Epi-iPSC2s 
maintained their Oct4 but downregulated Sox2, Nanog, Pecam1, Klf4, Stella and Rex1 
as determined by Q-PCR (Figure 4.9A). The early lineage markers Nodal, Pitx2, 
Brachyury, Gata6, Otx2, Foxa2 and Fgf5 increased to a level similar to embryo-derived 
EpiSCs (Figure 4.9B). These findings demonstrate that iPSC1 and iPSC2 can 
differentiate to EpiSC-like state, and are developmentally upstream to postimplantation 
epiblast. 
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Figure 4.8 Characterization of EpiSCs derived from iPSC1 and iPSC2 
(A) Morphology of Epi-iPSC1 and Epi-iPSC2 cultured in N2B27 medium containing 
Activin and FGF2. (B-E) Antibody staining for Oct4, Sox2, SSEA1 and Otx2. Scale bar, 
100μm.  
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Figure 4.9 Q-PCR analysis for early embryonic gene markers of Epi-iPSC1 and 
Epi-iPSC2. 
Q-PCR analysis of early embryonic gene markers in ESC, Epi-iPSC1, Epi-iPSC2 and 
embryo-derived EpiSCs. (A) Epi-iPSC1 and Epi-iPSC2 displayed similar profile to 
EpiSCs rather than ESCs, shown by the maintenance of Oct4 and reduced level of Sox2, 
Nanog, Pecam1, Klf4, Stella and Rex1. (B) The expressions of Nodal, Pitx2, Brachyury, 
Gata6, Otx2, Foxa2 and Fgf5 by Epi-iPSC1 and Epi-iPSC2 were detected at a similar 
level to EpiSCs. Gene expression was normalized to β-Actin and shown as relative 
level to ESCs. 
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4.9 Dual-responsive iPSCs exhibit accelerated differentiation kinetics  
When cultured in GMEM/FCS medium in bacterial grade petri dishes, iPSC1 and 
iPSC2 were able to generate EBs with similar size to those formed by ESCs (Figure 
4.10A). These iPSC-EBs, initially all Oct4-GFP+, significantly downregulated GFP 
expression at day 6 of culture (Figure 4.10B). Q-PCR analysis showed that the levels of 
Oct4 and Nanog transcripts in the EBs formed by iPSC1 and iPSC2 decreased rapidly 
during differentiation (Figure 4.11). When differentiated in N2B27 medium, a 
condition that favors neural fate conversion (Figure 4.12A), iPSC1 and iPSC2 
upregulated Pax6 at day 6 while no pronounced increase in Pax6 level was observed in 
ESCs until day 12 (Figure 4.12B). While the level of Nestin peak at day 12 for both 
iPSC lines and ESCs, the relative expression level in iPSCs at day 8 and day 10 were 
higher than that in ESC (Figure 4.12C). Tubb3 in iPSC1 and iPSC2 began to increase at 
day 10 of differentiation. However, its level did not rise until day 12 in ESC (Figure 
4.12D). When differentiated in GMEM/FCS medium (Figure 4.11A), I observed an 
upregulation of Brachyury at day 6 of differentiation, while iPSC1 and iPSC2 increased 
their Brachyury transcript 2 days earlier (Figure 4.13A). The expression of another 
early mesoderm marker gene Goosecoid was detected at day 6 in cultures of both iPSC 
lines, which was 2 days earlier than that in ESCs (Figure 4.13B). The level of Bmp4 
started to rise at day 6 in ESCs, whereas this happened at day 4 of differentiation in the 
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iPSC cultures (Figure 4.13C). The level of Afp in iPSCs began to increase at day 10 of 
differentiation, while prominent upregulation of Afp in ESC cultures was only observed 
from day 12 (Figure 4.13D). Together, these observations demonstrate that iPSC1 and 
iPSC2 differentiate faster toward major lineages in vitro in comparison to ESCs. 
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Figure 4.10 Embryoid body differentiation of iPSC1 and iPSC2 
(A) EBs formed by iPSC1 and iPSC2. (B) Oct4-GFP expression in day 3 and day 6 
EBs. Scale bar, 100μm. 
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Figure 4.11 Loss of pluripotent gene expression during EB differentiation of 
iPSC1 and iPSC2 
(A) Scheme of EB differentiation in GMEM/FCS medium. iPSC1 and iPSC2 were 
plated in bacterial grade petri dishes and cells were collected and were analyzed by 
Q-PCR every other day. (C-D) Decreased level of Oct4 and Nanog were observed as 
differentiation progress. Relative gene expression level was determined by normalizing 
to β-Actin. Scale bar, 100μm. 
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Figure 4.12 Neural differentiation of iPSC1 and iPSC2 
(A) iPSC1, iPSC2 and ESCs were subjected to EB differentiation in N2B27. The 
expression levels of stage specific neural gene marker (B) Pax6, (C) Nestin and (D) 
Tubb3 was analyzed by Q-PCR. Relative gene expression level was normalized to 
β-Actin.  
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Figure 4.13 Mesodermal and endodermal differentiation in iPSC1 and iPSC2 
iPSC1, iPSC2 and ESCs were subjected to EB differentiation in GMEM/FCS. The 
expression levels of mesodermal gene marker (A) Brachyury, (B) Goosecoid, and 
endodermal gene marker (C) Bmp4, (D) Afp were analyzed by Q-PCR. Relative gene 
expression level was normalized to β-Actin.  
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4.10 iPSCs revert to ICM-like ground state in 2i-LIF.  
ESCs cultured in 2i-LIF appear to form a homogeneous population that stays in a 
naïve ground state (Wray et al., 2010). Thus I put iPSC1 and iPSC2 back to the 2i-LIF 
condition to investigate potential changes in cell state. No adverse effect (eg. cell death, 
differentiation was observed when iPSC1 and iPSC2 were reverted from GMEM/FCS 
plus LIF to 2i-LIF condition (Figure 4.14A). Gene expression analysis was performed 
in 2i-iPSC1 and 2i-iPSC2 after three passages in 2i-LIF condition. 2i-iPSC1 expressed 
comparable levels of Klf4, Oct4, and Sox2 to ESCs cultured in LIF condition (Figure 
4.14B). The levels of Rex1, Stella, Pecam1 and Nanog were higher in 2i-iPSC1 than 
those in ESCs. 2i-iPSC2 expressed similar levels of Pecam1, Oct4, and Sox2 to ESCs, 
but higher levels of Rex1, Stella, Klf4 and Nanog than ESCs. The expression profile of 
early lineage marker genes showed comparable levels of Gata6 between 2i-iPSC1 and 
ESCs (Figure 4.14C). The levels of Pitx2, Nodal, Foxa2, Brachyury, Otx2 and Fgf5 
were lower in 2i-iPSC1 than those in ESCs. 2i-iPSC2 displayed lower expression level 
in all tested early lineage gene markers than ESCs. This transcription patterns indicates 
that 2i-LIF condition drives iPSC1 and iPSC2 to an earlier ICM-like state.  
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Figure 4.14 Morphological and early embryonic gene marker expression patterns 
in 2i-iPSC1 and 2i-iPSC2 
(A) iPSC1 and iPSC2 cultured in 2i-LIF condition (2i-iPSC) formed colonies with few 
differentiated cells in periphery. (B-C) The early embryonic gene marker expression of 
ESCs, 2i-iPSC1 and 2i-iPSC2 were analyzed by Q-PCR. (B) Rex1, Stella and Pecam1, 
Klf4, Nanog, Sox2 and Oct4. (C) Pitx2, Nodal, Brachyury, Foxa2, Otx2, Gata6 and 
Fgf5. Gene expression was normalized to β-Actin and shown as relative level to ESCs. 
Scale bar, 100μm. 
140
4.11 Differentiation kinetics of 2i-iPSCs  
To understand whether the shift in cell state had any effect on the temporal kinetics 
of lineage commitment, I performed EB differentiation of 2i-iPSC1 and 2i-iPSC2 and 
examined the temporal expression of a panel of somatic gene markers. Under neural 
differentiation condition in N2B27, 2i-iPSC1 and 2i-iPSC2 displayed similar temporal 
expression kinetics of Pax6, Nestin and Tubb3 to ESCs (Figure 4.15). When 
differentiated in GMEM/FCS medium that favour mesoderm and endoderm 
differentiation, I also observed a similar temporal upregulation of Brachyury, 
Goosecoid, Bmp4 and Afp between 2i-iPSC and ESC cultures (Figure 4.16).  
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Figure 4.15 Neural differentiation of 2i-iPSC1 and 2i-iPSC2 
(A) 2i-iPSC1, 2i-iPSC2 and ESCs were subjected to EB differentiation in N2B27. The 
expression levels of stage specific neural gene marker (B) Pax6, (C) Nestin and (D) 
Tubb3 was analyzed by Q-PCR. Relative gene expression level was normalized to 
β-Actin.  
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Figure 4.16 Mesodermal and endodermal differentiation in 2i-iPSC1 and 
2i-iPSC2 
2i-iPSC1, 2i-iPSC2 and ESCs were subjected to EB differentiation in GMEM/FCS. 
The expression levels of mesodermal gene marker (A) Brachyury, (B) Goosecoid, and 
endodermal gene marker (C) Bmp4, (D) Afp were analyzed by Q-PCR. Relative gene 
expression level was normalized to β-Actin.  
 
  
143
4.12 Summary 
In this chapter, the responsiveness of four iPSC lines to Activin and LIF was tested. 
Two of them (iPSC1 and iPSC2) were able to responsive to both LIF and Activin. The 
early embryonic gene expression and histone modification patterns demonstrated 
iPSC1 and iPSC2 existed in an intermediate cell state between ICM and 
postimplantation epiblasts. This advanced cell state was supporteded by their temporal 
differentiation kinetics compared to ESCs. After a brief exposure to 2i-LIF condition, 
these iPSC1 and iPSC2 were reverted to ground ICM-like state, and display a similar 
temporal kinetics of lineage commitment to ESCs. These data demonstrate that culture 
conditions affect cell state of iPSCs and their differentiation behaviour. From an 
applied standpoint of view, these intermediate-stated pluripotent cells may be 
beneficial for efficient lineage commitment.  
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Chapter 5 Microarray Analysis of ESCs, ALSCs and EpiSCs 
 
5.1 Introduction 
My findings described in chapters 3 and 4 raised many questions: how similar and 
different in global gene expression profile between cells of intermediate pluripotent 
state from that of ESCs and EpiSCs, and can one identify these intermediate-stated cells 
by molecular markers? To begin to address these questions, I performed a microarray 
analysis to compare the transcriptome of ESCs, ALSC, iPSC1 and EpiSCs.  
Microarray technology provides a powerful tool to catch a snapshot of the 
transcriptome within a population of cells. Such analysis has introduced a new type of 
investigation in many researches, such as looking for disease biomarkers, investigating 
genes involved in the pathogenesis of disease, pharmaceutical or toxic screening, 
identifying pathways in specific cell types that are activated by a compound (Butte, 
2002). A microarray is composed of a series of spots on a chip. Each spot contains 
multiple probes of the same cDNA. Once the cells or tissues have been generated, total 
RNA is extracted and then reversed-transcribed into cDNA. The cDNA sequence is 
then transcribed into biotin-labelled cRNA, which serves as probes to hybridize to the 
microarrays. Then microarray is scanned to reveal the spot that is hybridized by the 
146
cRNA (Lockhart and Winzeler, 2000; Schulze and Downward, 2001).   
Experiments assessing transcriptome alterations between cells in different 
pluripotent states have been performed previously. In the whole gene expression 
microarray study on FAB-SCs, the expression profile of a series of early embryonic 
gene markers was used to determine the intermediate cells state between ESCs and 
EpiSCs, and downregulation of a cell adhesion molecule, E-cadherin, was considered 
to play a critical role in the acquisition of pluripotency (Chou et al., 2008). This study 
demonstrated the application of microarrays to investigate the cell state between 
different cell lines and search for potential molecular markers for a novel cell type. 
However, the likely heterogeneous nature of FAB-SCs limits the impact of these data 
as signature of an intermediate pluripotent state. Bao and colleagues compared the 
transcriptome between ESCs and the transient transitional state during reversion from 
EpiSCs to ESC-like state (Bao et al., 2009). This study provides important information 
for transcriptional alterations during the transition from postimplantation epiblast to 
ICM stage, albeit no stable intermediate cell line was sustained during this 
reprogramming. Characterisation of transcriptome of the intermediate pluripotent state 
using a clonal-derived cell lines, as performed in this chapter, will reveal more detalis 
to what extent their expression profiles change, and what the molecular markers for 
identification of this cell population.  
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5.2 Hierachical clustering according to similarity 
Gene expression alterations of a limited number of early embryonic gene markers 
presented in previous chapters suggest an intermediate cell state of ALSCs, iPSC1 and 
iPSC2 between ESCs and EpiSCs. To consolidate this finding, Affymetrix Mouse 
Expression-Array-430.2.0 genechip, covering 45101 gene entities, was used to 
determine the transcriptional profiles of cell lines including ESC and iPSC1 (cultured 
in LIF condition), ALSC1 and iPSC1-A (cultured in Activin condition), Epi-ALSC1 
and Epi-iPSC1 (EpiSC-like cells). To investigate the reversibility of ALSCs in LIF 
condition, ALSC1 cultured in LIF condition for 3 passages (ALSC1-L) was also 
recruited in this study. A total of 21 arrays including triplicates for each cell line were 
used in this experiment. 
Hierachical clustering analysis was carried out to understand the relationship 
between different cell lines. To decrease the interference of unspecific hybridization 
background, gene entities with the signal intensity percentile lower than 20% in all 
samples were filtered out and a total of 42101 genes were recruited for the analysis. 
Epi-ALSC1, Epi-iPSC1 and iPSC1-A are within the same cluster, while iPSC1, 
ALSC1, ALSC1-L and ESCs were grouped together (Figure 5.1A). The correlation 
matrix further demonstrated that iPSC1 and ALSC1 were in a state between ESCs and 
Epi-iPSC1/Epi-ALSC1. iPSC1-A was more similar to Epi-iPSC1/Epi-ALSC1 than 
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iPSC1, while ALSC1-L were closer to ESCs than ALSC1 (Figure 5.1B).  
ALSC1 was derived from E14Tg2a ESCs on 129 genetic background, while 
iPSC1was reprogrammed from neural stem cells of 129/MF1 hybrid background. Thus 
it is possible that the distinct genetic background in individual cell line partially 
contributed to the global gene expression profile and affected the result of hierarchical 
clustering. Thus the cell lines with 129 backgrounds, including ESC, ALSC1, 
ALSC1-L and Epi-ALSC1, were reclustered using 41174 gene entities displaying 
signal intensity percentile higher than 20% in at least one of the triplicate samples. 
Again, Epi-ALSC1 was clustered away from ALSC1, ALSC1-L and ESCs (Figure 
5.2A). ESCs and ALSC1-L, both cultured in LIF condition, were clustered together. 
ALSC1 was clustered between ALSC1-L and Epi-ALSC1. The correlation matrix also 
demonstrated the same pattern of similarity, consolidating that ALSC1 was in a state 
between ESCs and Epi-ALSC1. Furthermore, LIF induced a reversion of ALSC1 to a 
state much closer to ESCs. 
The same strategy was also applied to iPSC1, iPSC1-A and Epi-iPSC1 and a total 
of 40681 genes were used for the hierarchical clustering analysis. iPSC1-A was located 
between Epi-iPSC1 and iPSC1 (Figure 5.3A). This relationship was also shown by 
correlation matrix (Figure 5.3B). Taken together, the data shown here demonstrate that 
Activin drives cells forward to a state closer to EpiSCs, while LIF moves them back to 
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ESC-like state.  
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Figure 5.1 Hierachical clustering analysis of all of 7 cell lines according to 
similarity 
Gene expression profile across 42101 gene entities was compared. (A) Data from the 
same cell lines were clustered to each other demonstrating good biological triplication. 
Epi-iPSC1 and Epi-ALSC1 and iPSC1-A displayed similar expression patterns and 
were grouped together, while iPSC1, ALSC1, ALSC1-L and ESCs formed another 
clustering group. (B) The correlation matrix demonstrated the level of similarity 
between each cell line  
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Figure 5.2 Hierachical clustering analysis of ALSCs and ESCs 
Gene expression profile across 41174 gene entities was compared between Epi-ALSC1, 
ALSC1, ALSC1-L and ESCs. (A) ALSC1, ALSC1-L and ESCs displayed similar 
expression patterns and were grouped together, while apparent different expression 
pattern can be observed in Epi-ALSC1. (B) The correlation matrix demonstrated the 
gene expression pattern of ALSC1 was situated between that of Epi-ALSC1 and ESCs. 
   
152
 
Figure 5.3 Hierachical clustering analysis of iPSCs 
Gene expression profile across 40681 gene entities was compared Epi-iPSC1, iPSC1-A 
and iPSC1. (A) iPSC1-A and iPSC1 displayed similar expression patterns and were 
grouped together, while apparent different expression pattern was observed in 
Epi-iPSC1. (B) The correlation matrix demonstrated the gene expression pattern of 
iPSC1-A was situated between that of Epi-iPSC1 and iPSC1.  
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5.3 Expression patterns of early embryonic gene markers 
The microarray analysis provides a power tool to systematically identify genes to 
be important for the transition of multiple pluripotent states. These could be previously 
characterized or novel genes. Given that data concerning known regulators of 
pluripotency are available from the array, I focused on the entities of a serial of early 
embryonic gene markers and examined their expression pattern across different cell 
lines. Genes specifically expressed in ICM, such as Nanog, Rex1, Klf4, Pecam1, Tbx3, 
Daz1, Stra8, Nr0b1 and Fbx15, were highly expressed in ESC and ALSC1-L, and 
demonstrated a downregulation gradient from iPSC1 to Epi-iPSC1/Epi-ALSC1 (Figure 
5.4). Conversely, Pitx2, Foxa2, Otx2, Brachyury, Nodal, Eomes and Fgf5 were 
expressed at a high level in Epi-iPSC1, Epi-ALSC1, whereas their levels in ALSC1, 
iPSC1, ALSC-L and ESC were relatively lower. However, while Q-PCR detected a 
downregulation of Stella in ALSC1 and iPSC1 compared to ESCs, an opposite 
direction of regulation was shown by microarray. Nevertheless, these data correlate 
well with the Q-PCR analysis described in previous chapters, providing an independent 
support of the intermediate cell state of ALSCs and iPSC1.  
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Figure 5.4 Microarray gene expression heat map of a selection of early 
embryonic gene markers in iPSCs and ALSCs 
Nanog, Rex1, Klf4, Pecam1, Fbx15, Daz1, and Nr0b1 were demonstrated a 
downregulation gradient from ESC/ALSC-L to Epi-iPSC1/Epi-ALSC1, while Pitx2, 
Foxa2, Otx2, Brachyury, Nodal, Eomes and Fgf5 display an upregulation gradient from 
ESC/ALSC-L to Epi-iPSC1/Epi-ALSC1.  
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5.4 Gene markers associated with the cells in the intermediate pluripotent state 
The expression profiles of microarray could identify gene markers that have not 
previously been characterised yet. To identify candidate gene entities differentially 
associated with ALSC1, Student’s t-test was performed by comparing the signal 
intensities of ALSC1 and ESCs with a p-value cut-off of 0.001. A filtering criteria of 
fold change ≥ 2 was also applied to improve the sensitivity of this screening. This 
relatively stringent analysis identified 499 gene entities showing significant differential 
expression between ALSC1 and ESC. The same screening strategy was also performed 
to ALSC1 and Epi-ALSC1 and 1407 gene entities were identified as differentially 
expressed. By overlapping above two groups, 153 gene entities were identified as 
candidate gene markers for ALSC1 (Figure 5.5A). According to their changes during 
the progression of cell states, these gene entities can be classified into 4 subgroups. 31 
genes belong to group 1. These genes were upregulated in ALSC1 but downregulated 
in either ESC or Epi-ALSC1 (Figure 5.5B, Appendix 3). 24 genes downregulated in 
ALSC1 but upregulated in ESC and Epi-ALSC1 were designated as group 2 (Figure 
5.5C, Appendix 3). Group 3 contained 32 genes showing highest level of expression in 
Epi-ALSC1 and lowest in ESCs (Figure 5.5D, Appendix 3). Lastly, 66 genes in group 4 
showed highest level of expression in ESC and lowest in Epi-ALSC1 (Figure 5.5E, 
Appendix 3). However, the trend of expression of these genes does not fully apply to 
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iPSCs cultured in either LIF or Activin and Epi-iPSC. For example, a significant 
proportion of group1 and group 2 genes are expressed at similar level in iPSCs cultured 
irrespective of culture condition (Figure 5.6). Furthermore, many group 3 and 4 genes 
were expressed at a similar level in iPSC-A and Epi-iPSC Thus, this data indicate that 
only a limited number of genes may be shared by ALSCs and iPSCs.  
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Figure 5.5 Comparison of transcriptome in ESCs, ALSCs and EpiSCs 
(A) 499 genes entities showing significant expression changes (p < 0.001, fold change 
≥ 2) between ALSC1 and ESC were identified, while 1407 entities showed altered 
expression by comparing ALSC1 with Epi-ALSC1. 153 gene entities were overlapped 
by comparing the list of gene entities of these two groups. (B) 31 gene entities showed 
upregulation in ALSC1 comparing to either ESC or Epi-ALSC1. (C) 24 were 
downregulated in ALSC1 in comparison with ESC or Epi-ALSC1. (D) 32 of them were 
expressed at a lowest level by ESCs, at a highest level by Epi-ALSC1. (E) 66 of them 
were at a highest level by ESCs, but expressed at lowest level by Epi-ALSC1. The top 
10 most differentially expressed gene entities by a comparison between ALSC1 and 
ESC were listed.  
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Figure 5.6 Expression patterns of the candidate gene markers for ALSCs across 
different pluripotent cell lines 
The expression patterns of 153 candidate markers for ALSC1 were demonstrated by 
heat map (A) and expression graphs (B). Red bar: genes upregulated in ALSC1 but 
downregulated in ESC or Epi-ALSC1. Blue bar: genes downregulated in ALSC1 but 
upregulated in ESC and Epi-ALSC1. Green bar: genes showing highest expression by  
Epi-ALSC1 and lowest by ESCs. Yellow bar: genes showing highest expression by  
ESCs and lowest by Epi-ALSC1. 
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5.5 Expression patterns of signalling pathway genes involved in pluripotency 
Many signalling pathways have been identified that play roles in the maintanence 
of pluripotency. Through the analysis of genes that are present in the microarray, it is 
possible to identify the core genes in each signalling pathways in the transition between 
multiple pluripotent states by characterisation of expression changes in cells in 
different states. To enable such representations, the expression levels of ESCs will be 
referred to as 0 in all cases and if the expression increases by 100%, this will be referred 
to as 1, and if it decreases by 50% this will be -1, and so on. The relative expression 
value higher than 1 or lower than -1 will be considered as significance. 
 
5.5.1 Expression of genes implicated in Activin/Smad2/3 signalling 
Considering the importance of the Activin/Smad2/3 signalling pathways in the 
maintenance of ALSC1 and EpiSCs, it is suprising to find that there is relatively little 
changes in Activin receptors Actvr and Smad2/3/4 genes (Figure 5.7). The only 
significant change is the upregulation of Smad3, which displayed 1 or 1.5 times 
expression changes in Epi-iPSC1 and ALSC1 compared to that in ESC. This result is 
consistent to the data presented in Chapter 3.7, which indicated that the level of 
Smad2/3 was similar across ESCs, ALSCs and Epi-ALSCs (Figure 3.9).  
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Figure 5.7 Expression of gene components in Activin/Smad2/3 signalling 
The changing levels of Acvrs and Smad2/3/4 over the change of cell state were 
demonstrated by comparing to the level of each gene in ESCs. The levels of listed genes 
were expressed at a similar level in all cell lines except for Smad3, which displayed a 
1.5 times of upregulation in Epi-ALSC1.  
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5.5.2 Expression of Fgfs and Fgfrs  
FGF signalling also plays an important role in the regulation of pluripotency. 
Change of expression level was observed in different Fgf and Fgfr genes amongst ESCs, 
ALSCs, iPSCs and EpiSCs. Fgf4 appeared to be the most downregulated Fgf, 
decreasing to more than 10 fold in Epi-iPSC1 and Epi-ALSC1 compared to ESC 
(Figure 5.8). Fgf4 expression of iPSC1, ALSC1 and iPSC1-A was also downregulated 
to an intermediate level between that of ESC/ALSC-L and Epi-iPSC1/Epi-ALSC1. 
This finding is in line with Fgf4’s role in lineage commitment of pluripotent stem cells 
in vivo and in vitro (Feldman et al., 1995; Lanner and Rossant, 2010). Conversely, the 
most upregulated Fgf is Fgf5, which expression level increased dramatically to more 
than 10 fold in iPSC1, and more than 50 fold in Epi-iPSC1 and Epi-ALSC1. This 
increase mimics Fgf5 expression in early embryonic development (Hebert et al., 1991; 
Lanner and Rossant, 2010). Taken together, these findings suggest different members 
of Fgf and Fgfr families are likely to be involved in the establishment or stablization of 
cells in distinct pluripotent cell state. 
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Figure 5.8 Expression of Fgfs and Fgfrs 
The changing levels of Fgfs and Fgfrs over the change of cell state were demonstrated 
by comparing to the level of each gene in ESCs. Fgf1, Fgf4 and Fgf17 were 
downregulated in Epi-iPSC1 and Epi-ALSC1 compared to ESCs, while Epi-iPSC1 and 
Epi-ALSC1 expressed a higher level of Fgf5 than ESCs. .  
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5.5.3 Expression of genes important for LIF/STAT3 signalling 
    The self-renewal of ESCs, but not EpiSCs, is dependent on LIF/STAT3 signalling. I 
have found that the expression levels of Lif and Stat3 in LIF-independent Epi-iPSC1 
and Epi-ALSC1 were only slightly decreased compared to ESCs (Figure 5.9). However, 
the level of LIF receptor Lifr dramatically decreased in Epi-iPSC1 and Epi-ALSC1. 
This downregulation may abolish LIF mediated activation of STAT3 and its 
downstream targets, providing an explanation for the LIF-unresponsiveness in EpiSCs. 
Stat4, also expressed in ICM (Guo et al., 2010), showed a progressive decrease from 
ESCs to EpiSCs. A role of Stat4 in the maintenance of pluripotency remains unclear 
however. 
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Figure 5.9 Expression of the gene components in LIF/STAT3 signalling 
The changing levels of the components of LIF/STAT3 signalling over the change of cell 
state were demonstrated by comparing to the expression of each gene by ESCs. Lifr and 
Stat4 were downregulated in Epi-iPSC1 and Epi-ALSC1 compared to ESCs.  
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5.6 Summary 
The microarray analysis presented here compared the gene expression profile 
amongst ESCs, ALSCs, iPSC1 and EpiSCs. This study provide strong independent 
evidence that ALSCs and some of the iPSC lines exist in distinct developmental state 
from that of ESCs and EpiSCs. The hierachical analysis consolidated the finding that 
Activin responsive cells are in an intermediate state between ESCs and EpiSCs. A 
number of genes markers were identified to be specifically up- or downregulated in the 
cells of this intermediate state. Most of the genes involved in Activin/Smad/2/3 
signalling were expressed at similar levels across different pluripotent states. 
Expression diversity was observed in the members of Fgfs, such as Fgf5 displayed an 
incremental changes while Fgf4 downregulated during the transition from ESC-like to 
EpiSC-like state. The expression of Lif and Stat3 remains similar in different 
pluripotent cell state, whereas Lifr and Stat4 significantly downregulated in EpiSC-like 
cells. These findings have identified novel genes that may have a functional role in 
pluripotency.
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Chapter 6 General Discussion 
ESCs have been reported to exist in a metastable pluripotent state with 
subpopulations of cells fluctuate between ICM- and epiblast-like state, as indicated by 
gene expression profile and epigenetic marker patterns (Hayashi et al., 2008; Toyooka 
et al., 2008). However, a stable clonogenic cell line in such intermediate cell state had 
not been identified thus far. In this thesis, novel stable intermediate pluripotent cell 
lines ALSCs have been derived at single cell level from ESC population. The 
successful isolation of these cells supports the notion that traverse from naïve ground 
state towards lineage commitment occurs gradually in which transition milestones can 
be captured as stable clonogenic entity, providing a good opportunity to investigate the 
morphological and functional properties of cells in this intermediate state.  
 
6.1 Extrinsic environment influences the cell states of pluripotent cell lines  
It has been shown that mouse epiblast or established EpiSC can be reverted to 
chimera-competent pluripotent stem cell when cultured on feeders in LIF and serum 
(Bao et al., 2009). Analysis of gene expression and epigenetic changes during this 
reprogramming process suggests that this reversion is progressive and there are 
multiple pluripotent states between ESCs and EpiSCs. The data presented in this thesis 
169
collectively demonstrates that the environmental cues affect the pluripotent cells to 
implement a stable state (Figure 6.1). 
 
6.1.1 “Naïve” ICM-like ground state defined by 2i-LIF condition 
During embryonic development, the entire fetus is generated from 
preimplantatory ICM, and each single cell, isolated at this stage, can contribute to all 
lineages (Gardner, 1998). Therefore, preimplantation ICM is considered as the naïve 
ground state. Mouse ESCs, derived at this time point, retain fully pluripotent potential 
and, when injected into blastocysts, are capable of colonising embryonic development 
by integrating into ICM and generate somatic and germ cells (Bradley et al., 1984). The 
mostly used condition for mouse ESC maintenance is medium containing serum with 
the addition of LIF (Smith et al., 1988). Mouse ESCs in such condition present 
heterogeneous expression of transcription factors, such as Nanog, Rex1 and Stella 
(Chambers et al., 2003; Hayashi et al., 2008; Toyooka et al., 2008). ESC colonies 
formed in serum-LIF are mixed with undifferentiated and differentiated cells (Wray et 
al., 2010). Recently a serum-free condition with LIF and two small molecules (2i-LIF), 
which block ERK signalling and suppress GSK-3β, has been shown to be sufficient to 
stabilize and sustain mouse ESCs with full pluripotency (Ying et al., 2008).  In 2i-LIF 
medium, mouse ESCs form colonies consisting of pure undifferentiated cells (Wray et 
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al., 2010).  The protein levels of Nanog or Rex1 are homogenously expressed at high 
level in all ESCs (Wray et al., 2010). 2i-LIF condition also facilitates the 
reprogramming of mouse iPSC lines to naïve ground state (Silva et al., 2008; Silva et al., 
2009). As presented in this thesis, the intermediate-stated iPSCs cultured in traditional 
serum-LIF condition can be reverted to naive ground state by 2i-LIF condition. 
Compared to ESCs cultured in serum-LIF condition, the gene expression levels of Rex1, 
Stella and Nanog are higher in the reverted 2i-iPSCs. These studies support the role of 
2i-LIF condition in the establishment and/or maintenance of the ground ICM-like state. 
Comparing the ICM contribution efficiency by morula aggregation between pluripotent 
cells cultured in serum-LIF and 2i-LIF conditions may provide further support that 
dual-signalling inhibitions promote to ground state. 
 
6.1.2 “Primed” epiblast-like state captured by Activin/FGF2 condition 
The serum-free N2B27 condition with addition of Activin and FGF2 can derive 
EpiSCs from either postimplantation epiblast or mouse ESCs (Guo et al., 2009). Mouse 
EpiSCs and ESCs exhibit distinct gene expression and epigenetic patterns that reflects 
their developmental state in the embryo (Brons et al., 2007; Tesar et al., 2007). Similar 
to postimplantation epiblast cells, EpiSCs do not contribute chimeric embryos (Brons 
et al., 2007; Brook and Gardner, 1997; Tesar et al., 2007). Their high expression levels 
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of early lineage gene markers suggest that EpiSCs may represent late epiblast that is 
primed to commit lineage differentiation (Bao et al., 2009; Chou et al., 2008).  
     
6.1.3 “Primed” intermediate state in serum-containing condition 
Mouse ESCs cultured in traditional serum-LIF condition contains a small 
proportion of cells express low level of Nanog, Rex1 and Stella (Chambers et al., 2007; 
Hayashi et al., 2008; Toyooka et al., 2008). These Nanog-, Stella- or Rex1- ESCs are 
biased for differentiation (Chambers et al., 2007; Hayashi et al., 2008; Toyooka et al., 
2008). The gene expression pattern of Stella- and Rex1- ESCs are closer to a 
postimplantation epiblast (Hayashi et al., 2008; Toyooka et al., 2008). For all of the 
three markers, sorted fractions of pure positive or negative subpopulation can 
regenerate the parental heterogeneous population (Hayashi et al., 2008; Toyooka et al., 
2008). This suggests that in serum-LIF condition the mouse ESCs are truly in a 
metastable state in which dynamic balance exists between ground and primed states. In 
this thesis, I found that Activin plus serum can support clonal self-renewal of cells in a 
primed state (ALSCs). The early embryonic gene expression patterns suggest that 
ALSCs are in an intermediate cell state between ESCs and EpiSCs. Although ALSCs 
are poised to differentiation, they display distinct gene expression or functional 
characteristics from Nanog-, Stella- or Rex1-ESC subpopulations. ALSCs expressed 
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low levels of a serial of pluripotent markers including Rex1, Stella, Fbx15 and Nr0b1, 
while these genes were expressed in Nanog- ESCs. Both ALSCs and Nanog- ESCs 
integrate to embryo proper but only Nanog- ESCs are able to generate live-born 
chimera. Stella- ESCs seldom form EBs, whereas EBs are efficient generated by 
ALSCs. Rex1- ESCs are unable to contribute to embryonic tissues. Considering their 
gene expression pattern, ALSCs are likely a partition of ESCs expressing low levels of 
Nanog, Rex1 and Stella captured by serum-Activin condition. It is also possible that the 
Nanog-. Rex1- or Stella- ESC fraction can adapt to the serum-Activin condition and 
converted to the state similar to ALSCs. Single cell analysis by culturing the 
FACS-sorted ESC fraction in serum-Activin condition would be helpful to clarify the 
origin of ALSCs.  
Although ground state iPSCs has been successfully reprogrammed in serum-LIF 
conditions (Hanna et al., 2009; Kaji et al., 2009; Kim et al., 2009; Kim et al., 2008; 
Lyssiotis et al., 2009; Maherali et al., 2007; Meissner et al., 2007; Okita et al., 2007; Shi 
et al., 2008; Wernig et al., 2008; Wernig et al., 2007; Woltjen et al., 2009; Yusa et al., 
2009; Zhou et al., 2009), some reported partial reprogramming in this culture condition 
(Mikkelsen et al., 2008; Silva et al., 2008; Silva et al., 2009). These pre-iPSCs exhibit 
incomplete expression of pluripotency associated genes and can be rapidly 
reprogrammed to the ground state in 2i-LIF condition (Silva et al., 2008; Silva et al., 
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2009). In this thesis, I found that the two iPSC lines exist at an intermediate state in 
serum-LIF condition, while their cell state can be reverted to ground state by 2i-LIF 
condition. A residual epigenetic memory of lineage commitment genes left by 
transcription factor reprogramming may affect their acquisition/maintanence of 
ground state in serum-LIF condition.  
 
6.2 Human ESCs and multiple pluripotent states  
Human ESCs are derived from ICM of human blastocysts (Thomson et al., 1998). 
Similar to mouse ESCs, they maintain prolonged undifferentiated proliferation, can 
differentiate to three germ-layers, and express key pluripotent transcription factors 
Oct4, Sox2 and Nanog. However, their self-renewal and pluripotency are dependent on 
distinct signalling pathways from mouse ESCs. Serum-LIF condition, which support 
mouse ESCs cultures (Smith et al., 1988), induces differentiation in human ESCs 
(Thomson et al., 1998). It has been shown that the components of LIF/STAT3 signalling 
are expressed at very low levels in human ESCs (Brandenberger et al., 2004). The 
addition of JAKI did not induce differentiation in human ESCs (Hanna et al., 2010). In 
contrast, FGF2/ERK and Activin/Smad2/3 signalling are required to maintain the 
self-renewal of human ESCs in culture (Vallier et al., 2005). The blockage of these 
signalling pathways attenuates Nanog expression in human ESCs (Greber et al., 2008; 
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Greber et al., 2010). This requirement of Activin/Smad2/3 and FGF2/ERK suggests 
that human ESCs might in fact be an in vitro equivalence of EpiSCs (Brons et al., 2007; 
Tesar et al., 2007).  
EpiSCs share a number of features with human ESCs, including a similar fattened 
colony morphology, and dependence on Activin/Smad2/3 and FGF/ERK signalling 
(Brons et al., 2007; Tesar et al., 2007). However, these two cell types display distinct 
molecular features. ICM markers Rex1 and Klf4 are expressed in human ESCs, but 
nearly absent in EpiSCs (Chan et al., 2009; Darr et al., 2006; Nakagawa et al., 2008). 
Epiblast marker Fgf5 are not detected in human ESCs, but highly expressed in EpiSCs 
(Darr et al., 2006). These gene expression differences suggest an earlier developmental 
state of human ESCs than that of EpiSCs.    
A recent study has shown that human ESCs can be reverted to ICM-like state by 
exogeneous expression of Oct4, Sox2 and Klf4 in 2i-LIF condition (Hanna et al., 2010). 
These “Naïve” human ESCs and mouse ESCs share similar gene expression pattern, 
LIF/STAT3 signalling dependency and capability to generate chimera. Hough and 
colleagues dissected single cells from special zone of human ESC colonies for 
transcriptional analysis and found a positional expression gradient of pluripotent genes 
(Hough et al., 2009). Cells at the edge of colony consistently expressed Oct4. 20% of 
cells in the middle of colonies lost the expression of Oct4, while 40% of cells in the 
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center of colonies did not express Oct4. The level of Oct4 in each single cell is higher at 
the edge than that in the center of colonies. These studies suggest that multiple cell 
states may also exist in human ESCs. It would be interesting to know if the cell state of 
dual-responsivness to LIF and Activin is also presented in human ESCs.  
 
6.3 The signalling responsiveness of different pluripotent cell states. 
A striking feature of the Activin responsive cells is their unique responsiveness to 
signalling pathways. As presented in this thesis, ALSCs, iPSC1 and iPSC2 efficiently 
form undifferentiated colonies in either LIF or Activin conditions. This dual 
responsiveness to LIF/STAT3 and Activin/Smad2/3 signalling pathways is further 
confirmed by their response to JAK and Activin inhibitor treatments. Moreover, the 
induction of pluripotent marker Klf4 following treatment of ERK inhibitors suggested a 
role for ERK signalling in the maintenance of their undifferentiation status. These 
features reveal the unique signalling responsiveness of cells in an intermediate state.   
LIF sustains self-renewal of mouse ESCs and iPSCs by activating JAK and 
STAT3 (Matsuda et al., 1999; Niwa et al., 1998; Smith et al., 1988). Consistent with 
published reports, a short treatment of LIF in mouse ESCs results in STAT3 
phosphorylation and a significant induction of Socs3, Errb and Klf4 (Yang et al., 
2010). In contrast, EpiSCs do not respond to LIF (Brons et al., 2007; Tesar et al., 
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2007), and the expression levels of Socs3, Errb and Klf4 are not altered by the 
treatment of LIF. Furthermore, my microarray analysis demonstrated the 
downregulation of LIF receptor Lifr in EpiSCs compared to ALSCs, iPSCs and ESCs. 
(Figure 5.9). This observation suggests that the lack of Lifr in EpiSCs may impede the 
activation and induction of the downstream targets driven by LIF, attributing to the 
absence of LIF-responsiveness in EpiSCs.  
Activin/SMAD2/3 signalling is a key mechanism for the self-renewal of EpiSCs. 
Inactivation of the Smad2/3 pathway promotes neuroectodermal differentiation, which 
can be prevented by constitutive Nanog expression (Vallier et al., 2009). In contrast, 
Activin/Smad2/3 signalling does not seem to promote Nanog expression and 
self-renewal in mouse ESCs (Greber et al., 2010). The short treatment of Activin 
cannot induce the expression of Nanog in ESCs, despite the Smad2 can be 
phosphorylated by Activin. My data suggest that Smad2/3 signalling is likely to control 
Nanog expression in ALSCs, as in EpiSCs. Considering its critical role in the 
maintenance of pluripotency, the Nanog induction could explain the 
Activin-responsiveness in ALSCs. On the other hand, although Nanog is not a 
downstream target of Smad2/3 signalling in mouse ESCs, the possibility that Activin 
may activate the expression of pluripotent genes other than Nanog in mouse ESCs 
cannot be ruled out.  
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By suppressing ERK signalling, ALSCs and mouse ESCs exhibit similar response, 
suggesting both cell lines share similar intracellular regulatory machinery of ERK 
signalling. It has been shown that the activation of ERK signalling promotes neural 
differentiation in mouse ESCs (Stavridis et al., 2007). Conversely, blocking ERK 
signalling by a chemical inhibitor allows mouse ESCs to retain pluripotency and 
undergo self-renewal (Stavridis et al., 2007). Erk2-null ESCs are also unable to make 
the transition from pluripotency to neural lineage commitment when LIF is removed 
(Kunath et al., 2007). These results indicate that the activation of ERK signalling is 
needed for mouse ESCs to initiate differentiation. On the other hand, ERK signalling 
in EpiSCs has been demonstrated to act by inhibiting both reversion to a mouse 
ESC-like state and differentiation forward to the neural lineage (Greber et al., 2010). 
Thus, the modulation of ERK signalling is a key element in the control and 
identification of the different stem cell states.  
     
6.4 Molecular gene markers for the intermediate cells 
My microarray experiments identified a number of gene markers for ALSCs and 
iPSC-A. Most of them had not been characterized in literature. Further examination of 
the role of these gene candidates and the exact populations that they express would be 
necessary to identify their exact function in pluripotent cells.  
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6.4.1 Gbp1 and Gbp3 
Gbp1 and Gbp3 encode members of guanylate-binding proteins, which appear to 
be involved in host pathogen interactions in response to Interferon-gamma (Degrandi et 
al., 2007). Gbp1 is expressed at intestinal epithelial cells in response to 
Interferon-gamma (Boehm et al., 1997). Overexpression of Gbp1 leads to inhibition of 
viral replication and growth of endothelial cells (Anderson et al., 1999; Guenzi et al., 
2001), while downregulation of Gbp1 results in enhanced permeability that correlates 
with increased apoptosis (Schnoor et al., 2008). It is possible that Gbp1 is an important 
marker of intestinal mucosal inflammation and this upregulation could be a protection 
of epithelial cells (Schnoor et al., 2008). However, its role in pluripotent or multipotent 
stem cells has not been revealed yet in literature. 
In addition to an Interferon-response gene, Gbp3 may be a marker for erythroid 
differentiation (Han et al., 1998). Its expression is clearly induced while differentiating 
erythroid progenitors to reticulocytes by erythropoietin. The role of Gbp3 in pluripotent 
cells is still unknown.  
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6.4.2 Lefty2 
The protein encoded by Lefty2 plays an important role in left-right determination 
during embryogenesis. It is expressed exclusively on the left side of the mid-gestational 
mouse embryos (Meno et al., 1996). Lefty2-null mouse embryos demonstrated an 
expansion of Nodal expression, which results in an extension of the primitive streak 
and mesoderm (Meno et al., 1999). The expression of Pitx2, a downstream target of 
Nodal (Shiratori et al., 2001), is symmetrical rather than specific on the left side in the 
mutant embryos (Meno et al., 2001). Thus Lefty2 could serve as a feedback inhibitor to 
restrict the long range effect of Nodal on the right side during establishment of the 
left-right axis. 
Although Nodal and Activin share the same receptor binding site to control the 
activation of Smad2/3 signalling (Kelber et al., 2008), it has been shown that lefty2 is 
unable to inhibit signalling by Activin (Chen and Shen, 2004). Its role in the 
establishment/maintenance of pluripotent state remains unclear.  
 
6.4.3 Il33 
Protein encoded by Il33, Interleukin-33 (IL-33), is a member of the IL-1 cytokine 
family, which is considered to be crucial for induction of host defense responses against 
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nematodes and allergic diseases (Oboki et al., 2010). The expression of Il33 is found in 
virtually all tissue but particularly in pulmonary and epidermal epithelium and central 
nervous system (Onda et al., 1999; Schmitz et al., 2005). Mice with injection of IL-33 
generate splenomegaly with an increased expression of serum IgE, IgA, IL-5, and 
IL-13 (Schmitz et al., 2005). The treatment with IL-33 significantly reduces the 
mortality of sepsis in mice (Alves-Filho et al., 2010). Il33 also works on promotion of 
angiogenesis by increasing proliferation, migration, and differentiation of endothelial 
cells (Choi et al., 2009), suggesting its additional role in vascular regeneration. 
However, its expression pattern in early embryos and role in pluripotent stem cells has 
not been reported.  
 
6.4.4 Oasl2 
Oasl2 encodes a member of 2′-5′-Oligoadenylate synthetases (OAS) family 
(Eskildsen et al., 2002), which are important components of an interferon-mediated 
antiviral pathway and apoptosis (Castelli et al., 1998; Zhou et al., 1993). The 
2′-5′-oligoadenylates (2-5A) synthesized by OAS activate RNase L, which then blocks 
viral proliferation by degradation of cellular and viral RNA (Zhou et al., 1993). The 
expression of OAS is clearly induced while differentiate mouse myeloid cells to mature 
macrophages by IL-6 (Salzberg et al., 1997), suggesting their role in myeloid 
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differentiation. However, the report about the function and regulation of Oasl2 has not 
been presented in literature.   
 
6.5 Lineage commitment of Activin responsive intermediate stem cells.  
Pluripotent stem cells have the potential to generate all cell types of the body, 
raising great prospect for biomedical applications. However, it is still a great challenge 
in controlling their differentiation and producing right type of disease relevant cells in 
vitro.  
Advances in developmental biology have made it possible to recapitulate the key 
events that regulate early lineage commitment of the embryo in stem cell cultures. The 
key issue for generating specific somatic cell population from pluripotent stem cells is 
to direct differentiation toward the desired progenitor cell fate by culture environments 
and then to move them to the next stage by appropriate stimuli such as growth factors. 
However, pluripotent stem cell differentiation is still variable and inefficient (Hu et al., 
2010). One of the reasons may be the inconsistency of responsiveness to culture 
environments.  
Stem cells in different pluripotent states have distinct intracellular signal 
transduction pathways and display distinct potential for cell commitment. For example, 
BMP4 has been reported to be required for mouse ESC self-renewal, while it promotes 
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non-neural lineage differentiation and suppresses neural commitment in EpiSCs 
(Zhang et al., 2010). As described before, the inhibition of ERK signalling induce the 
expression of neural genes in EpiSCs, but not in mouse ESCs and ALSCs. The 
activation of Activin/Smad/2/3 signalling increased the expression of Nanog in ALSCs 
and EpiSCs, while the level of Nanog did not change in ESCs by the same treatment. 
Considering the heterogeneity of multiple pluripotent states in ESC population, it is 
very likely that only a proportion of ESCs display appropriate response to a given 
differentiation condition and committ to desired cell phenotypes, while distinct 
response from other ESC fractions may generates undesired cell types. This issue is 
supported by the finding that neural fate commitment occurs much reliable and 
efficiently from EpiSCs (unpublished observations). Thus the synchronicity of the cell 
state before/during differentiation could play a critical role in lineage/cell fate 
commitment. A better understanding the cellular state of stem cells of interest and their 
signalling responsiveness would facilitate the development of tailored strategies for 
lineage/cell type commitment.  
 
6.6 Future perspectives  
The isolation of Activin responsive stem cells from ESC and iPSCs provides new 
insights into the role of growth factor culture conditions in the induction or stabilisation 
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of stem cell pluripotent states, also serving a platform for dissecting the molecular 
regulation during the transition from ESC- to EpiSC-like state. This study raise 
interesting questions whether cells like ALSCs could be derived directly from 
postimplantation epiblast. Despite their capability to form chimeric embryos, no 
live-born chimeras were produced by ALSC-injected embryos. The reversion of 
ALSCs and iPSCs to ICM-like state by serum-LIF or 2i/LIF also needs to be confirmed 
by chimeric assay. Nevertheless, the data presented here provide a culture condition to 
derive the intermediate pluripotent cell state from ESC population. It would be fruitful 
to compare the epigenomic, proteomic and miRNA expression profile between cell 
lines in different pluripotent states to understand the regulatory mechanisms involved 
in the transition between different pluripotent states. A real-time study of 
reprogramming process from somatic cells bearing multiple reporters for pluripotency 
in different culture environments would enable monitoring of the transition from 
somatic cells to different pluripotent states. Elucidation of this process would yield a 
more refined understanding of the pluripotent states, and may improve the 
understanding of molecular reprogramming and induced pluripotent states. From a 
technical stand point, the synchronization of cell states would be useful for many 
applications, including differentiation and reprogramming technologies. The 
realization that the state of pluripotent stem cells can be determined by culture 
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conditions would probably help us to utilize these pluripotent cells more efficiently in 
future studies. 
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Figure 6.1 Proposed model for the pluripotent state of ALSCs, iPSC1 and iPSC2 
ALSCs, and iPSC1 and iPSC2 stand in an intermediate cell state between ESCs and 
EpiSCs. Activin keeps the intermediate cell state in ALSCs, while LIF reverts them to 
ESC-like state. The intermediate state of iPSC1 and iPSC2 can be maintained either by 
LIF or Activin. Notable, ALSC1, iPSC1 and iPSC2 express lower levels of ICM 
markers Rex1 and Stella, and higher levels of postimplantation epiblast markers Fgf5 
and Otx2 compared to ESCs. Pluripotent cells in an intermediate state are biased toward 
differentiation. 
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Appendices 
Appendix 1 Karyotypes of ESC, iPSC1, iPSC2, ALSC1 and ALSC2 
Cell line Karyotype (30 cells analyzed per cell line) 
ESC 41(3); 40(25); 39(1); 38(1) 
iPSC1 41(1); 40(27); 39(2) 
iPSC2 41(2); 40(25), 39(3) 
ALSC1 41(2); 40(24), 39(3). 38(1)  
ALSC2 41(2); 40(26), 39(2) 
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Appendix 2 pCAGGFPIP plasmid map 
 
 
 
 
 
204
Appendix 3 List of gene entities differentially expressed in ALSCs 
Probe Set Entrez Gene Gene Symbol 
Fold change  
(ALSC1 vs ESC)
Fold change    (ALSC 
vs Epi-ALSC1) 
1453511 71874 2310007B03Rik 11.06481 11.53396 
1418392_a 55932 Gbp3 8.01534 3.893338 
1420549 14468 Gbp1 6.943485 2.436364 
1436227 320202 Lefty2 6.476628 9.993758 
1456414 5.022646 7.867327 
1416200 77125 Il33 4.993092 4.647886 
1453196_a 23962 Oasl2 4.841561 2.088584 
1423323 56753 Tacstd2 4.685701 4.276065 
1449195_s 73708 Cxcl16 4.410352 13.90719 
1448566 66102 Slc40a1 4.092808 4.09911 
1427735_a 53945 Acta1 4.083665 5.503626 
1427126 11459 Hspa1b 3.815536 4.539298 
1417061 15511 Slc40a1 3.362889 2.352151 
1447845_s 53945 Vnn1 3.15434 8.913751 
1447657_s 22361 Synpo2l 3.13049 3.508112 
1427127_x 68760 Hspa1b 3.0372 5.381081 
1450947 15511 2610528J11Rik 3.013181 2.983249 
1455422_x 66451 Sept4 2.950449 6.584262 
1418486 18952 Vnn1 2.945981 6.536784 
1419161_a 22361 Nox4 2.7131 2.426342 
1452318_a 15511 Hspa1b 2.696918 5.337349 
1448729_a 18952 Sept4 2.686173 5.05456 
1437492 210719 Mkx 2.564387 3.141417 
1418421 12029 Bcl6b 2.542156 3.292718 
1427095 109332 Cdcp1 2.459411 4.450863 
1427344_s 75141 Rasd2 2.307177 2.744508 
1447851_x 11982 Atp10a 2.271987 2.879133 
1452013 11982 Atp10a 2.242464 2.256396 
1416411 14863 Gstm2 2.240391 3.804982 
1419356 93691 Klf7 2.198096 2.744891 
205
1434227 64661 Krtdap 2.194268 2.314972 
1415871 21810 Tgfbi -7.02742 -11.0453 
1418926 21417 Zeb1 -7.02057 -4.90636 
1448123_s 21810 Tgfbi -6.80776 -9.15399 
1429177_x 20671 Sox17 -6.35916 -96.7233 
1457424 14048 Eya1 -4.09892 -3.85303 
1415938 20730 Spink3 -3.6617 -8.93062 
1426864_a 17967 Ncam1 -3.46598 -5.87017 
1418863 14463 Gata4 -3.2714 -18.3238 
1428650 21961 Tns1 -3.07987 -3.3643 
1440084 -2.96874 -2.40758 
1456225_x 228775 Trib3 -2.96324 -2.0277 
1459900 97294 C79468 -2.93665 -3.2476 
1421113 58803 Pga5 -2.81358 -78.2841 
1439906 -2.64124 -2.00197 
1428891 231440 9130213B05Rik -2.61625 -10.6763 
1429273 73230 Bmper -2.26614 -19.703 
1428136 20377 Sfrp1 -2.256 -14.2711 
1433907 208076 Pknox2 -2.2371 -8.5293 
1437921_x 329003 Zfp516 -2.2251 -2.2188 
1445186 20856 Stc2 -2.15461 -2.11979 
1428284 329540 8430427H17Rik -2.12207 -3.86795 
1449403 18585 Pde9a -2.08794 -2.06553 
1424711 83921 Tmem2 -2.08147 -3.09134 
1436546 -2.04878 -3.81902 
1438883 14176 Fgf5 19.22372 -3.77459 
1419304 20997 Brachyury 10.24256 -4.09983 
1435172 13813 Eomes 4.228427 -5.03912 
1448737 21912 Tspan7 4.014822 -4.0191 
1455494 12842 Col1a1 3.767909 -3.80776 
1434458 14313 Fst 3.212809 -3.61895 
1416832 67547 Slc39a8 3.1448 -12.3958 
1426914 218518 Marveld2 3.107973 -2.29636 
1452092 77590 4631426J05Rik 2.943198 -3.69747 
206
1450047 50786 Hs6st2 2.925034 -2.35306 
1433776 108927 Lhfp 2.826924 -3.44778 
1448590 12833 Col6a1 2.623209 -3.32078 
1457651_x 140743 Rem2 2.55755 -2.33522 
1455238 245631 Mum1l1 2.553514 -6.10264 
1417301 14368 Fzd6 2.47981 -3.30419 
1427442_a 11820 App 2.459312 -2.09502 
1454866_s 209195 Clic6 2.430571 -25.2 
1434301 399603 D330050I23Rik 2.395443 -2.25483 
1428647 676870 Pbx1 2.37119 -2.57186 
1438658_a 13610 S1pr3 2.369889 -3.94598 
1454890 27494 Amot 2.298599 -4.50251 
1416034 12484 Cd24a 2.279596 -4.01032 
1440179_x 268291 Rnf217 2.23479 -2.14651 
1427086 2.231409 -5.85575 
1448694 16476 Jun 2.193931 -2.13919 
1435083 330695 Ctxn1 2.189578 -2.24953 
1448620 14131 Fcgr3 2.151947 -2.33264 
1455297 278240 Spin2 2.150102 -3.21319 
1423110 12843 Col1a2 2.14247 -13.2384 
1439364_a 17390 Mmp2 2.08138 -2.7662 
1427056 235130 Adamts15 2.079683 -3.88903 
1423825 68151 Gpr177 2.026444 -2.24079 
1430781 78801 Ak7 -11.3853 5.073378 
1426413 18012 Neurod1 -10.6432 2.15579 
1441957_x 73673 2410076I21Rik -9.32805 2.587716 
1423523 30956 Aass -5.14343 2.782167 
1448029 21386 Tbx3 -4.96035 5.509306 
1424713 75600 Calml4 -4.90764 6.359205 
1416697 13482 Dpp4 -4.71297 3.215269 
1455214 17342 Mitf -4.68638 3.147517 
1418215 17288 Mep1b -4.51108 6.507727 
1436742_a 381411 Accsl -4.50243 5.260548 
1418395 67473 Slc47a1 -4.24445 3.890261 
207
1455695 20449 St8sia1 -4.23551 2.874574 
1436568 67374 Jam2 -4.01851 13.05776 
1426511 71733 Susd2 -3.85629 8.441291 
1422071 16857 Lgals6 -3.79824 5.144615 
1429483 76815 Calcoco2 -3.68679 8.76297 
1420337 14472 Gbx2 -3.6624 5.163305 
1431416_a 67374 Jam2 -3.45276 10.93872 
1421618 17916 Myo1f -3.26369 4.411918 
1449408 67374 Jam2 -3.19989 27.62439 
1422573 11717 Ampd3 -3.17922 2.394315 
1439958 100038982 100038982 -3.16074 5.597023 
1431143_x 71361 Aifm2 -3.13811 5.383742 
1420773 13531 Dub1 -3.07908 9.707236 
1433785 17433 Mobp -3.03055 2.687414 
1457026 239759 Liph -2.98845 4.050774 
1423327 68172 Rpl39l -2.90908 51.04577 
1432227 -2.87338 6.405481 
1427479 641136 Eif1a  -2.84767 6.88959 
1460512_a 68307 Lrriq4 -2.78194 2.47379 
1419695 20449 St8sia1 -2.74397 2.905306 
1428685 74075 Syce1 -2.69662 8.437688 
1450764 27052 Aoah -2.67759 8.685411 
1457033 
434555 
632758 
665902 
665913 
Zscan4-ps2 
Zscan4-ps3 
Zscan4c 
Zscan4f 
-2.67351 31.95352 
1460454 69824 Glod5 -2.66666 4.970747 
1438474 213121 Ankrd35 -2.59872 6.116093 
1453628_s 74249 Lrrc2 -2.56714 6.792891 
1431417 67374 Jam2 -2.4735 10.67193 
1434873_a 100045877 Centb1 -2.39952 5.714676 
1436837 98558 Mael -2.3581 18.2438 
1418133 12051 Bcl3 -2.32926 11.00181 
1417395 16600 Klf4 -2.32382 9.907211 
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1456242 653016 EG653016 -2.32365 121.0736 
1453072 71862 Gpr160 -2.30644 3.456795 
1419759 18671 Abcb1a -2.28565 38.02187 
1444390 383491 Prdm14 -2.28179 43.55431 
1418895 54353 Skap2 -2.27147 2.539685 
1439759_x 73671 Sult6b1 -2.27001 5.350758 
1431630_a 100046855  Klf3 -2.23862 5.463916 
1428549 74186 Ccdc3 -2.23695 3.718158 
1438321_x 75007 Fam63a -2.23227 3.609042 
1449170 57746 Piwil2 -2.21548 9.503831 
1452016 11690 Alox5ap -2.19375 3.711375 
1422567 63913 Fam129a -2.16234 2.18277 
1459888 545261 LOC545261 -2.14091 3.201303 
1448499_a 13850 Ephx2 -2.13429 6.08563 
1456768_a 105450 Mmrn2 -2.13123 7.842351 
1437693 110957 D1Pas1 -2.1053 16.55183 
1436171 226652 Arhgap30 -2.08579 6.76628 
1434917 12808 Cobl -2.08255 4.433247 
1426981 18553 Pcsk6 -2.07869 3.179029 
1438933_x 19395 Rasgrp2 -2.0674 3.113059 
1422965 11610 Agtrap -2.04957 2.250919 
1424067 15894 Icam1 -2.03665 4.871396 
1449898 54204 Sept1 -2.03586 14.47731 
1460409 12894 Cpt1a -2.02208 11.20892 
 
 
